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ABSTRACT 
 
Liver disease is a common cause of morbidity and mortality in dogs. Liver diseases can be 
broadly classified into vascular abnormalities such as congenital portosystemic shunt (cPSS) 
and parenchymal diseases such as primary hepatitis. cPSS are a well-recognised vascular 
anomaly in dogs. Despite the importance of liver diseases as a cause of debilitating clinical 
signs, little is understood about the pathophysiology of the complications of canine liver 
disease and it is currently difficult to provide accurate prognostic information to owners of 




One of the most common complications of canine liver diseases is the development of 
neurological signs termed hepatic encephalopathy (HE). The pathogenesis of HE is poorly 
understood although increases in ammonia, manganese, gastrointestinal-derived endogenous 
benzodiazepines, cortisol and altered tryptophan metabolism have been linked to the 
development of neurological signs. Recent studies have also shown an association between 
inflammation and HE in dogs with cPSS. However, little is known about the role of 
manganese in the dogs with primary hepatitis and the relationship between inflammation and 
liver disease has only been crudely assessed to date using tools such as the systemic 




A small number of studies have examined prognostic markers in dogs with liver disease. 
However, none have examined the relationship between inflammation and outcome. This is 
surprising given the accumulating data in human hepatology which indicates that the 
presence of systemic inflammatory response syndrome (SIRS) is a common and debilitating 
event in patients with liver diseases. For example, the presence of SIRS has been linked to the 
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development of complications such as HE and is associated with a poor clinical outcome in 
humans with liver diseases. In contrast, the relationship between SIRS and clinical outcome 




This thesis aimed to advance understanding of the pathogenesis of hepatic encephalopathy in 
dogs with liver disease. In addition, the thesis aimed to examine the relationship between 
inflammation and clinical outcomes in dogs with liver disease. Specifically, the aim of this 
body of work was to examine manganese and sodium metabolism in dogs with primary 
hepatitis and to measure cytokines in dogs with a congenital portosystemic shunt. The final 
aim was to examine the relationship between systemic inflammatory response scores to 




This thesis demonstrated that a high SIRS score was associated with a poorer long term 
survival in dogs with primary hepatopathies. Furthermore, IL-6 concentrations were 
increased in dogs with a cPSS. Given the well-established role of IL-6 in the pathogenesis of 
hepatic encephalopathy in humans with acquired liver disease, it is possible that IL-6 may be 
important in the development of HE in dogs with a cPSS. This thesis also demonstrates that 
whole blood Mn concentrations are increased in dogs with primary hepatitis and sodium 
concentrations were rarely outside the reference range in dogs with primary hepatitis. This 
finding is in contrast with the numerous studies of human patients with liver disease. Overall, 
these findings highlight the potential role of dogs as a model to examine the pathogenesis of 
liver disease in human health. 
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LAY SUMMARY 
 
Liver disease is a common cause of morbidity and mortality in dogs. Liver diseases can be 
broadly classified into vascular abnormalities such as congenital portosystemic shunt (cPSS) 
and parenchymal diseases such as primary hepatitis. cPPS are a well-recognised vascular 
anomaly in dogs. One of the most common clinical signs in dogs with a cPSS is hepatic 
encephalopathy (HE), which leads to the development of neurological signs. Recent studies 
have also shown an association between inflammation and HE in dogs with cPSS. This is 




The underlying aetiology of most cases of canine primary hepatitis is unknown. 
Consequently, treatments are typically palliative and it is difficult to provide accurate 
prognostic information to owners. In human hepatology there is accumulating data which 
indicates that the presence of systemic inflammatory response syndrome (SIRS) is a common 
and debilitating event in patients with liver diseases. For example, the presence of SIRS has 
been linked to the development of complications such as HE and is associated with a poor 
clinical outcome in humans with liver diseases. In contrast, the relationship between SIRS 




This thesis aimed to better define the role of inflammation in the pathogenesis of canine liver 
disease. Additional aims were to assess the presence of sodium derangements and whole 
blood manganese concentrations in dogs with primary hepatitis. The hypothesis of this thesis 
was that markers of inflammation would be increased in dogs with liver diseases and would 
be negatively correlated with outcome. As similar findings have been demonstrated in human 
medicine, the hypothesis was that dogs would be suitable models for human liver disease. We 
Page | 9  
also hypothesised that whole blood manganese concentrations and derangements in serum 




This thesis demonstrates that a high SIRS score was associated with a poorer long term 
survival in dogs with primary hepatopathies. Furthermore, IL-6 concentrations were 
increased in dogs with a cPSS. Given the well-established role of IL-6 in the pathogenesis of 
hepatic encephalopathy in humans with acquired liver disease, it is possible that IL-6 may be 
important in the development of HE in dogs with a cPSS. This thesis also demonstrates that 
whole blood Mn concentrations are increased in dogs with primary hepatitis and sodium 
concentrations were rarely outside the reference range in dogs with primary hepatitis. This 
finding is in contrast with the numerous studies of human patients with liver disease. This 
study, and our earlier work in dogs with a cPSS, indicates that hyponatremia is uncommonly 
observed in dogs with liver disease. These findings highlight the potential role of dogs as a 
model to examine the pathogenesis of liver disease in human health. 







Liver disease is a common cause of morbidity and mortality in dogs [1]. Liver diseases can 
be broadly classified into vascular abnormalities such as congenital portosystemic shunt 
(cPSS) and parenchymal diseases such as primary hepatitis [2]. Primary hepatitis includes all 
inflammatory disorders of the hepatic parenchyma [2]. In contrast to human medicine, where 
the type of hepatitis is defined by the inciting cause, few causes of chronic hepatitis have 
been identified in the dog, and the majority of cases are idiopathic [2]. Primary hepatitis is an 
important cause of morbidity in humans [3]. In order to further explore the pathogenesis and 
efficacy of novel therapies, a large number of experimental models have been developed [4]. 
A widely used model involves the chronic administration of carbon tetrachloride (CCl4) to 
mice which results in liver fibrosis and cirrhosis [5]. However, it is clear that these models 
have important differences to human hepatitis both on the histopathological and molecular 
level [6]. Additionally, the well-controlled experimental set up using these models is very 
dissimilar to the variable human clinical situation [6]. Taken together, there is an unmet need 
for additional spontaneous models of hepatitis which better mimic human hepatitis and the 




1.2 Primary Hepatitis 
 
 
Primary hepatitis is well recognised in the dog, with one study reporting a clinical prevalence 
of 0.5% (Poldervaart et al., 2009). Primary hepatitis may be divided into acute and chronic 
forms, as well as lobular dissecting, granulomatous, and eosinophilic hepatitis as defined by 
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the WSAVA according to histological criteria (Van den Ingh et al., 2006). Of these, chronic 
hepatitis appears the most common (Poldervaart et al., 2009). Chronic hepatitis, which is 
used irrespective of the cause and is characterized by the presence of fibrosis, inflammation, 
hepatocellular apoptosis, and necrosis [8]. Irrespective of the nomenclature used, a 
morphologic diagnosis should emphasize the type, pattern, and extent of the necrosis and 
inflammation, as well as the possible cause, and in more prolonged disease, the presence, 
pattern, and extent of fibrosis and regeneration [9]. Chronic hepatitis is characterized by 
hepatocellular apoptosis or necrosis, a variable mononuclear or mixed inflammatory 
infiltrate, regeneration, and fibrosis. The proportion and distribution of these components 
vary widely, and it is necessary to include in the diagnosis the activity (determined by the 
quantity of inflammation and extent of hepatocellular apoptosis and necrosis) and the stage of 
the disease (determined by the extent and pattern of fibrosis and the possible presence of 




The clinical prevalence of chronic hepatitis may be an underestimate because post-mortem 
examination of 200 unselected dogs detected the presence of chronic hepatitis in 12% 
(Watson et al., 2010). In contrast to human medicine, where the type of hepatitis is defined 
by the inciting cause, few causes of chronic hepatitis have been identified in the dog, and the 
majority of cases are idiopathic (Watson, 2004). As a result, treatment is symptomatic 
(Watson, 2004) and the prognosis for dogs with chronic hepatitis is poor with a reported 
median survival time of 18.3 months (Poldervaart et al., 2009). 
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1.3 Congenital Portosystemic Shunts 
 
Congenital portosytemic shunts (cPSS) are well-recognised vascular anomalies in dogs. 
Clinical signs are associated with the volume and origin of blood bypassing the liver, resulting 
in impaired hepatic function, neurological dysfunction, chronic gastrointestinal signs, lower 
urinary tract signs and delayed growth [11]. Dogs suspected to have a cPSS can be screened 
with good sensitivity and specificity by measurement of serum bile acids and ammonia [12]. 
Various imaging modalities can be used to diagnose cPSS in dogs. In most cases the abnormal 
vessel can be identified using abdominal ultrasonography [13]. In a small proportion of 
equivocal cases, the vessel can be identified using computed tomographic angiography or direct 
visualisation or portovenography during coeliotomy [14]. Dogs with a cPSS are initially 
typically treated with a combination of antibiotics, lactulose and a low protein diet to ameliorate 
encephalopathy [11]. Once their condition has been stabilised, attenuation of the shunting 




1.4 Hepatic Encephalopathy 
 
One of the most common presenting signs in dogs with a liver disease is hepatic encephalopathy 
(HE), which encompasses a range of neurological disturbances that occur in dogs with liver 
disorders. Clinical signs can include ataxia, unresponsiveness, pacing,  circling, blindness, 
seizures and coma [11]. The pathogenesis of HE in dogs is not fully understood. 
Hyperammonaemia is considered the most important mediator of HE [16] since ammonia has 
been demonstrated to be neurotoxic and plasma concentrations are frequently increased in dogs 
with cPSS. However, the importance of ammonia in driving HE in dogs remains unclear since 
there is a paucity of studies which have examined whether ammonia 
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concentrations correlate to the presence and/or severity of HE in dogs and hyperammonaemia 
alone, which can occur in dogs with urea cycle enzyme deficiencies, does not typically result 
in HE [17]. Increased plasma concentrations of endogenous benzodiazepines have been 
demonstrated in dogs with cPSS which have been postulated to be important in causing HE 
[18]. Other studies have indicated a role for hypercortisolism [19], and altered tryptophan 
metabolism in the development of HE[20]. Altered manganese metabolism has also been 
implicated in the pathogenesis of HE as dogs with a cPSS have significantly increased whole 




1.5 Inflammation and Liver Disease 
 
Recently, a potential role of inflammation in initiating HE has been demonstrated in dogs  with 
a cPSS. It was found that dogs with a cPSS and HE had higher serum concentrations of c-
reactive protein (CRP), a widely used serum biomarker of inflammation, compared to dogs 
with a cPSS that were asymptomatic and healthy dogs [22]. Dogs with a cPSS that were 
asymptomatic did not have increased serum CRP concentrations compared to healthy dogs. 
This observation is similar to several human studies which have shown a strong positive 
correlation between inflammation and HE [23]. A systemic inflammatory response is 
frequently present in human patients with liver disease and has been shown to predict mortality 
and presence of HE [24]. Indeed, the induction of hyperammonaemia with the administration 
of amino acid solution to cirrhotic patients only resulted in the development of HE in the 
presence of a systemic inflammatory response [25]. A wide range of studies have explored the 
role of cytokines, which are a key part of the systemic inflammatory response, in patients with 
liver disorders with many identifying an increase in plasma concentrations of Interleukin-6  
(IL-6)  and  Tumour  Necrosis  Factor  alpha  (TNF-α).  For  example,     serum 
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concentrations of TNF-α, have been shown to correlate with increasing severity of HE due to 
chronic liver failure [26, 27]. Other studies have found that IL-6 concentrations are increased 




There is growing evidence that systemic inflammatory response syndrome (SIRS) is a 
common and serious disorder among human patients with liver diseases [29-31]. It has been 
suggested that the presence of SIRS can lead to a further deterioration in liver function 
resulting in significant morbidity and mortality [32, 33]. The presence of SIRS can 
compromise the function of various organ systems resulting in Multiple Organ Dysfunction 
Syndrome (MODS) [34]. In hospitalised human patients, cirrhotics with SIRS have more 
severe hepatic encephalopathy (HE), are more likely to develop hepatorenal syndrome and 
have non-reversible renal dysfunction [35]. In acute liver failure, the presence of SIRS, 
whether or not precipitated by infection, has been implicated in the progression of HE, 
reducing the chances of transplantation and conferring a poorer prognosis [24]. Furthermore, 
higher SIRS scores are related to the development of acute liver failure in patients with pre- 




The exact mechanism by which inflammation and hyperammonaemia modulate the 
neuropsychological function remains to be determined. Astrocytes are the main cells in the 
brain that metabolise ammonia. Ammonia is considered to initiate HE through the conversion 
of glutamate and ammonia to glutamine, often resulting in osmotic stress, astrocyte swelling, 
cerebral oedema and intracranial hypertension [37]. 
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1.6 Manganese and Liver Disease 
 
Many other factors may contribute to the pathogenesis of liver disease in dogs. The impact of 
primary hepatic disease on the metabolism of other trace elements is less well understood in 
dogs. In particular, the liver plays a pivotal role in Mn metabolism as the majority of gastro- 
intestinally absorbed Mn is removed by the liver and excreted into bile such that only 
approximately 2% of absorbed Mn reaches the systemic circulation (Aschner and Aschner, 
2005). One experimental study showed that healthy dogs fed large quantities of Mn daily for 
16 months showed no ill-effects and no appreciable increase in blood Mn concentrations. On 
post-mortem analysis, liver and bile had the highest concentrations of Mn (Reiman and 
Minot, 1920). Although Mn is an essential mineral, Mn toxicity has been reported in humans 
and also in experimental animal models (Keen et al., 2000). Studies in humans have shown 
increased blood Mn concentrations and Mn deposition in the CNS in cases of hepatic 
insufficiency (Mizoguchi et al., 2001; Rose et al., 1999; Tuschl et al., 2008; Versieck et al., 
1974). The deposition of Mn in the CNS is considered to play a role in hepatic 
encephalopathy and a direct relationship has been demonstrated between blood Mn 
concentration, MRI hyperintensity consistent with Mn deposition and severity of 
encephalopathic score in humans (Layrargues et al., 1995; Spahr et al., 1996). In the CNS, 
Mn is preferentially stored in astrocytes such that Mn concentrations in astrocytes may be 
almost 200 times the extracellular concentrations (Tholey et al. 1988). Astrocytes are the 
major cell implicated in the development of hepatic encephalopathy and dysfunction of the 
astrocyte by Mn is thought to contribute to this (Hazell et al., 2006; Shawcross and Jalan 
2005). 
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1.7 Sodium and Liver Disease 
 
Similar to humans, hyponatremia is often cited to be a complication of canine liver disease 
and liver disease is often quoted to be an important differential diagnoses of hyponatremia 
[38-41] . Hyponatremia has also been cited as an important factor in the development of HE 
in dogs [42, 43]. The severity of the hyponatremia has been linked directly to the severity of 
the cirrhosis in humans [44, 45]. Portal hypertension, diuretics, large volume paracentesis 
without administration of albumin and infection have been associated with the development 
or worsening of hyponatremia [45, 46]. The presence of hyponatremia frequently complicates 
the management of the cirrhotic patients and those awaiting liver transplants. In addition, 
hyponatremia is a risk factor for liver transplantation, being associated with a high frequency 
of complications and reduced short and long term post-transplant survival [44]. Prognostic 
models incorporating serum sodium concentrations were also better able to predict the 
urgency and need for transplant [44]. Hyponatremia was a strong predictor of the 
development of HE in a cohort of cirrhotic patients [47]. Despite the important implication of 
sodium in human liver disease, few studies have formally examined sodium homeostasis in 




1.8 Thesis Objectives 
 
Liver disease is a common cause of morbidity and mortality in dogs. The pathogenesis of 
liver disease (particularly primary hepatitis) is poorly understood. It is clear that the role of 
inflammation is important in the progression and prognosis in human patients with liver 
disease, but this is poorly defined in dogs. The general objective of this thesis was to better 
define the role of inflammation in canine liver disease and whether inflammation was linked 
to prognosis in these cases. Other factors that may contribute to pathogenesis such as sodium 
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and manganese were also examined. Furthermore, if the findings of this thesis mirrored those 
seen in human practice, then this thesis aimed to assess if cats and dogs could provide a 
model system to investigate human disease. 
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CHAPTER 2 
 




Primary hepatitis includes all inflammatory disorders of the hepatic parenchyma (consisting 
of the functional unit of liver lobule (12)), apart from those due to distant endotoxin release 
(12, 82). Primary hepatitis is well recognised in the dog, with one study reporting a clinical 




The liver has a key role in regulation of many trace elements and various trace element 
abnormalities have been documented in cases of canine chronic hepatitis (10, 87). Copper 
metabolism has been investigated most extensively and increased hepatic copper 
concentrations have been shown to be both a cause and effect of chronic hepatitis. In 
Bedlington Terriers a primary genetic defect results in copper accumulation within the 
hepatic parenchyma and subsequent hepatitis due to oxidative damage (69). Conversely, 
chronic hepatitis can result in reduced biliary excretion of copper and increased hepatic 
parenchymal concentrations (24). 
Similarly, increased hepatic iron concentrations have also been documented in naturally 
occurring and experimental canine chronic hepatitis (15, 28, 36). Zinc has been shown to be 
an effective treatment for copper associated hepatitis and hepatic and biliary zinc 
concentrations have been investigated in canine chronic hepatitis (22, 46, 86). 
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There have been only a small number of studies which have investigated the role of Mn in 
canine liver disease. MRI of 13 dogs and 3 cats with a congenital portosystemic shunt (cPSS) 
detected hyper-intense focal areas in the lentiform nuclei which were considered to be 
consistent with Mn deposition, although neither blood nor tissue Mn concentrations were 
assessed in this study (41). In support of this hypothesis, a single case has been reported of a 
Yorkshire Terrier with a cPSS and a compatible hyper-intense lentiform nucleus which had 
an increased concentration of Mn in this area on post mortem examination (52). Gow et al. 
have recently demonstrated that whole blood Mn concentrations are increased in cases of 
canine congenital porto-systemic shunting (90). However, it remains unclear whether dogs 




The central hypothesis of this study was that dogs with primary hepatitis have altered Mn 
homeostasis. The aim was to compare whole blood Mn concentrations in dogs with primary 
hepatitis with those in healthy dogs and in dogs with non-hepatic illness. A second hypothesis 
was that dogs with primary hepatopathies would not have such profound disturbances of Mn 
homeostasis as in dogs with a cPSS. This was investigated by comparing whole blood Mn 




2.2 Materials and Methods 
 
Cases of primary hepatitis, defined as dogs with increased fasting bile acid concentrations, 
and histopathological confirmation of primary hepatitis from samples collected by either 
biopsy or post-mortem examination were considered eligible for inclusion into the study. 
Disease was classified according to WSAVA criteria (22). The type of diet 
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during the past 7 days was noted for each dog. Consecutive cases of dogs with non-hepatic 
illness, defined as dogs with illness warranting diagnostic investigations including serum 
biochemistry which had serum concentrations of albumin, ALT, fasting bile acid 
concentrations and bilirubin within their respective reference ranges, were enrolled into the 
study. Dogs with congenital portosystemic shunting confirmed by ultrasonography and/or 
portovenography were also enrolled. Consecutive cases of healthy dogs, defined as dogs 
which were considered healthy by their owners and had a normal physical examination when 
blood sampled for an unrelated primary reason (rabies serology or PCV check before blood 




Whole blood samples were collected from fasted animals. Blood collected via a 21g 5/8” 
 
hypodermic needle during clinical jugular sampling was placed into commercial 1.3ml EDTA 
tubes and retained for Mn measurement. All EDTA samples were frozen within 4 hours of 
collection and stored at -70°C until they were transported on dry ice to the Scottish Trace 
Element and Micronutrient Reference Laboratory. Manganese concentrations were 
determined in whole blood by graphite furnace atomic absorption spectrometry after dilution 
with Triton X-100 solution. The inter-assay coefficient of variation (CV) was 5.4%. The 
inter-assay variation was calculated from 10 batches of three internal quality control samples 
of manganese. The mean Mn concentrations of the three control samples were 760 nmol/L, 
490 nmol/L and 320nmol/L; this approach ensured that the inter-assay CV was calculated 
using a range of Mn concentrations. In summary, both the inter- and intra-assay CVs were 
very low which would be expected with this analytical technology run from a national centre 
of excellence for trace element analysis (http://www.trace-elements.co.uk/). Assays CV in 
this range ensured that are our data, and the conclusions of the study, were highly robust. The 
 
study was approved by the University of Edinburgh Ethics Research Committee. 
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Manganese concentrations, and differences in age, were compared between the dogs with 
primary hepatitis, hospitalised ill dogs and healthy dogs by a Kruskal-Wallis test with post- 
test Dunn’s multiple comparison test. Manganese concentrations were compared between 
dogs with primary hepatitis and a cPSS by a Mann Whitney U test. The presence of 
correlation between Mn concentrations and biochemical values and age was evaluated by 
Spearman Rank Correlation test. Statistical analysis was performed with a commercial 
software package (GraphPad Prism version 5.0 for Windows, GraphPad Software) with 
p<0.05 considered significant. 
Page | 22  
2.3 Results 
 
The group of dogs with non-hepatic illness comprised 31 dogs (19 different breeds, 2 cross- 
breeds, 4 male entire, 10 male neutered, 13 female neutered, 4 female entire, mean age 59.5 
months, range 5 to 132 months).  The disease categories were; nasal disease (5), 
inflammatory disease (4), orthopaedic abnormalities (4), lower urinary disorders (6), poor 
body condition/ exercise intolerance (5), chronic renal failure (2), focal neoplasia (2) and one 
each of ovarian remnant syndrome, congenital cardiac disease and rodenticide exposure. 
Blood samples from healthy dogs were obtained from 16 blood donors and 2 dogs during 
rabies serology sampling (10 different breeds, one cross-breed, 4 male entire, 11 male 
neutered, 3 female neutered, mean age 57 months, range 24 to 120 months). 65 dogs with 
congenital portosystemic shunting (cPSS) (25 breeds, 8 crossbreeds, 21 male entire, 10 male 
 
neutered, 26 female entire, 8 female neutered, mean age 19 months, range 3 to 96 months) 
were also enrolled. Twenty one dogs diagnosed with primary hepatic disease were enrolled 
(10 different breeds, 6 cross-breeds, 4 male entire, 7 male neutered, 10 female neutered, mean 
age 84 months, range 6 to 180 months). Eight were confirmed from samples collected post- 
mortem, and four from a percutaneous spring-loaded biopsy instrument. Nine were collected 
by surgical biopsy techniques. Eighteen cases were diagnosed with chronic hepatitis, two 
cases with dissecting lobular hepatitis and one case with cirrhosis. Only one case was being 
fed a diet formulated for liver disease at the time of sampling.  The other twenty dogs were 
fed a standard proprietary dog food or home cooked diet. The dogs with non-hepatic illnesses 
and healthy dogs were fed a range of commercial non-clinical diets. There were no 
significant differences between the age of the dogs in the healthy, non-hepatic illness and 
primary hepatic disease groups (p=0.67). 
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There was a significant difference in Mn concentrations between dogs with primary hepatic 
disease, dogs with non-hepatic illness and healthy dogs (p<0.002, figure 1). Post test analysis 
revealed that there was no difference in Mn concentrations between dogs with non-hepatic 
illness and healthy dogs but a significant difference in Mn concentration between dogs with 
primary hepatic disease and dogs with non-hepatic illness (p<0.01) and dogs with primary 
hepatic disease and healthy dogs (p<0.05). In the primary hepatic disease group, there was no 
correlation between Mn and fasting bile acid concentrations (r=0.25, p=0.28), Mn and 
albumin (r=-0.19, p=0.41), Mn and ALT (r=-0.20, p=0.39), Mn and prothrombin time 
(r=0.18, p=0.48), Mn and activated thromboplastin time (r=0.35, p=0.16) or bilirubin and Mn 




Dogs with primary hepatitis had significantly lower whole blood Mn concentration compared 
to dogs with cPSS (median values 1101nmol/L and 2026 nmol/L respectively, p=0.0005) 







The central finding of this study was that whole blood Mn concentrations were significantly 
higher in dogs with primary hepatic disease compared to both healthy dogs and dogs with 
non-hepatic illness. Taken together with our earlier study, which reported that dogs with 
cPSS had increased Mn concentrations, it is clear that dogs with either primary vascular or 
primary hepatic disease frequently have disturbed Mn homeostasis (21). The first-pass 
excretion of gastrointestinally absorbed Mn relies on efficient delivery through the portal 
circulation, functional hepatocytes and functional biliary system.  Dysfunction of any 
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one of these three components will potentially increase delivery of Mn to the systemic 
circulation (14, 21). Chronic hepatitis and lobular dissecting hepatitis commonly result in 
dysfunction of all three components; hepatocyte loss by definition in chronic hepatitis, 
cholestasis due to hepatic architecture disruption of the biliary system and, due to increased 
portal pressure, recruitment of porto-systemic collateral vessels (31). Consequently, it is 
technically challenging to establish the relative importance of primary parenchymal diseases, 
cholestasis and portosystemic shunting on Mn metabolism. This issue has been partially 
addressed in experimental models of liver disease; a study of CNS Mn deposition in the rat 
found that rats with induced portocaval shunts had higher concentrations than rats with 
induced cirrhosis.  The shunting percentage was 100% for induced shunts whereas cirrhotic 
rats shunting percentage ranged from 29-100% (42).  One clinical study of humans with 
cirrhosis demonstrated that all nine patients with hyperintense lesions on MRI had shunting 
vessels compared to only 2 of 17 patients with no lesions on MRI (59). In the present study, 
the finding that whole blood Mn concentrations were significantly higher in dogs with cPSS 
compared to dogs with primary hepatopathy would suggest that shunting vessels have an 
important role in the pathogenesis of hypermanganesaemia. A further study investigating any 
correlation between whole blood Mn concentrations with the percentage shunting in dogs 




Investigation of whole blood Mn concentrations in cases of acute hepatitis may help define 
the contribution of hepatic dysfunction per se to increased Mn concentrations. One study of 
acute hepatitis in humans demonstrated increased serum concentrations of Mn in acute 
hepatitis and found correlation with activity of serum aminotransferase in both acute and 
chronic hepatitis which may suggest that hepatic dysfunction rather than development of 
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porto-systemic shunting was responsible for the increased systemic concentrations of Mn in 
these cases (91). Determination of systemic whole blood Mn concentrations in cases of 
extra-hepatic cholestasis would also be useful to assess the contribution of biliary 




Manganese and iron metabolism are intimately linked. Both metals use divalent metal 
transporter 1 (DMT1) for absorption from the gastrointestinal tract and also transport into the 
CNS (84).MT1 expression in both is regulated by iron status via hepcidin (12, 29). 
Deficiency of iron has been shown to increase CNS Mn uptake whilst iron overload 
decreases Mn uptake (72). 
Hepcidin is mainly produced by hepatocytes and is up-regulated in response to inflammation 
(43, 72). Because chronic hepatitis (by definition) and to a lesser extent lobular dissecting 
hepatitis have an inflammatory component, it would be expected that hepcidin may be up-
regulated and this, in turn, would reduce gastro-intestinal absorption of Mn (18). In 
converse, loss of hepatocytes would reduce the liver’s ability to produce hepcidin and thus 
potentially remove negative regulation of DMT1 expression. In support of this, serum 
hepcidin and prohepcidin concentrations have been found to be lower in humans with 
chronic hepatitis C compared to healthy controls and correlate with fibrosis (4, 34). 
Therefore it is likely that the confounding interplay of inflammation, reduced of hepatic 
function, effects of iron status on hepcidin expression and therefore gastro-intestinal Mn 
uptake may play a role in the variation in Mn concentrations found in the primary 
hepatopathy group. 
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In the primary hepatitis group, 5 dogs had whole blood Mn concentrations which were 
markedly elevated whilst the remaining 16 had similar concentrations to the non-hepatic 
illness and healthy groups. This apparent split may be due to a difference in hepatic reserve, 
or as stated above, due to differing shunt fractions, and larger studies to assess if histological 




The main pathological consequence of increased Mn concentrations in hepatic disorders is 
considered to be neurological dysfunction. The exact mechanism by which Mn causes 
encephalopathy is unclear although there are both in-vitro and in-vivo studies which suggest 
that many of the effects are centred on the astrocyte, a key cell in the development of hepatic 
encephalopathy (35). Astrocytes have been shown to have a high affinity transport 
mechanism for Mn and cytoplasmic Mn accumulation causes Alzheimer type II changes, 
which are recognized in post-mortem examination of human hepatic encephalopathy patients 
(26, 92). Experimental studies have demonstrated a wide variety of potential toxic effects of 
Mn on the astrocyte, including potentiating the effect of ammonia as well as impairing their 
glutamate transport (71). Glutamate is the main excitatory neurotransmitter in the brain, and 
astrocyte uptake is the main method of removal from the synaptic cleft. Glutamate is then 
converted to glutamine by the astrocyte before being recycled back to the neuron. Inhibition 
of the astrocyte glutamate transporter GLT-1 by Mn prevents this inactivation and recycling, 
potentially causing increased concentrations of the neurotransmitter in the synaptic cleft 
(24). Astrocyte mitochondrial dysfunction and induction of peripheral-type benzodiazepine 
receptors (PTBR, now termed translocator protein) with increased ligand binding have also 
been reported with increasing concentrations of Mn (36, 57). Activation of the PTBR causes 
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neurosteroid production, which are also implicated in astrocyte dysfunction and hepatic 




The finding that Mn concentrations are increased in some dogs with primary hepatopathies 
may be therapeutically relevant since chelation treatment with para-aminobenzoic acid and 
disodium edetate has been used successfully in human cases of Mn toxicity (33, 75). This 
has led to the suggestion that it may be of use in controlling Mn and thus hepatic 
encephalopathy in humans and dogs (22, 36, 48). In support of this, Park et al. (2008) used 
trientine chelation therapy in one human case of chronic hepatic disease with acquired 
portosystemic shunting and hepatic encephalopathy. Following treatment there was a 
decrease in whole blood Mn concentrations and a reduction in CNS MRI hyperintensity 
which was thought to be consistent with a reduction in CNS Mn deposition. These findings 






The present study demonstrates that whole blood Mn concentrations are increased in dogs 
with primary hepatitis. The prognostic significance of increased Mn concentrations, 
correlation with severity of histopathological changes or acquired shunting fraction and the 
relationship between Mn and severity of HE in dogs is deserving of further study. 



















Figure 1: Whole blood manganese concentrations (nmol/l) in dogs with primary hepatitis 














Figure 1: Whole blood manganese concentrations (nmol/l) in dogs with primary hepatitis 
(liver), dogs with non-hepatic illness (hospitalised) and healthy dogs (healthy). 
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Congenital portosytemic shunts (cPSS) are well-recognised vascular anomalies in dogs. 
Clinical signs are associated with the volume and origin of blood bypassing the liver, resulting 
in impaired hepatic function, neurological dysfunction, chronic gastrointestinal signs, lower 
urinary tract signs and delayed growth[11]. Dogs suspected to have a cPSS can be screened 
with good sensitivity and specificity by measurement of serum bile acids and ammonia [12]. 
Various imaging modalities can be used to diagnose cPSS in dogs. In most cases the abnormal 
vessel can be identified using abdominal ultrasonography [13]. In a small proportion of 
equivocal cases, the vessel can be identified using computed tomographic angiography or direct 
visualisation or portovenography during coeliotomy[14]. Dogs with a cPSS are initially 
typically treated with a combination of antibiotics, lactulose and a low protein diet to ameliorate 
encephalopathy[11]. Once their condition has been stabilised, attenuation of the shunting vessel 




One of the most common presenting signs in dogs with a cPSS is hepatic encephalopathy (HE), 
which encompasses a range of neurological disturbances that occur in dogs with liver disorders. 
Clinical signs can include ataxia, unresponsiveness, pacing, circling, blindness, seizures and 
coma[11]. The pathogenesis of HE in dogs with a cPSS is not fully understood. 
Hyperammonaemia is considered the most important mediator of HE[16] since ammonia has 
been demonstrated to be neurotoxic and plasma concentrations are frequently increased in 
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dogs with cPSS. However, the importance of ammonia in driving HE in dogs remains unclear 
since there is a paucity of studies which have examined whether ammonia concentrations 
correlate to the presence and/or severity of HE in dogs and hyperammonaemia alone, which 
can occur in dogs with urea cycle enzyme deficiencies, does not typically result in HE[17]. 
Increased plasma concentrations of endogenous benzodiazepines have been demonstrated in 
dogs with cPSS which have been postulated to be important in causing HE[18]. Other studies 
have indicated a role for hypercortisolism[19], and altered tryptophan metabolism in the 
development of HE[20]. Altered manganese metabolism has also been implicated in the 





Recently, we have demonstrated a potential role of inflammation in initiating HE in dogs  with 
a cPSS. We found that dogs with a cPSS and HE had higher serum concentrations of c- reactive 
protein (CRP), a widely used serum biomarker of inflammation, compared to dogs with a cPSS 
that were asymptomatic and healthy dogs [22]. Dogs with a cPSS that were asymptomatic did 
not have increased serum CRP concentrations compared to healthy dogs. This observation is 
similar to several human studies which have shown a strong positive correlation between 
inflammation and HE[23]. A systemic inflammatory response is frequently present in human 
patients with liver disease and has been shown to predict mortality and presence of HE[24]. 
Indeed, the induction of hyperammonaemia with the administration of amino acid solution to 
cirrhotic patients only resulted in the development of HE in the presence of a systemic 
inflammatory response[25]. A wide range of studies have explored the role of cytokines, which 
are a key part of the systemic inflammatory response, in patients with liver disorders with many 
identifying an increase in plasma concentrations of Interleukin-6  (IL-6)  and  Tumour  Necrosis  
Factor  alpha  (TNF-α).  For  example,     serum 
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concentrations of TNF-α, have been shown to correlate with increasing severity of HE due to 
chronic liver failure [26, 27]. Other studies have found that IL-6 concentrations are increased 




Despite the expanding interest in the role of cytokines in the development of HE in human 
patients with liver diseases, the concentrations of pro-inflammatory plasma cytokines  have not 
been examined in a cohort of dogs with a confirmed cPSS. Therefore, the aim of the  study was 
to measure plasma IL-2, IL-6, IL-8 and TNF-α concentrations in healthy dogs and dogs 
diagnosed with a cPSS. We hypothesised that IL-6 and TNF-α concentrations would be 




3.2 Materials and Methods 
 
Consecutive cases of dogs with a cPSS were considered suitable for inclusion into the study. 
Dogs were diagnosed with a cPSS if the dog had compatible clinical signs and had an abnormal 
shunting vessel identified via ultrasonography, computerised tomography, intra- operative 
portovenography, visualised during surgery or by a combination of methods. Dogs which had 
signs of neurological dysfunction such as altered behaviour, pacing, circling, altered mentation, 
stupor or seizures within the previous 24 hours were classified as having HE and this was 
recorded at the time of blood sampling. Consecutive cases of healthy dogs, who were being 
blood sampled for routine preventive healthcare reasons, were also considered eligible for 
inclusion into the study. Healthy dogs were defined as dogs which were considered healthy by 
their owners and that had a normal physical examination. Venous blood samples were collected 
from both the cPSS and healthy dogs and immediately placed 
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into lithium heparin blood collection tubes. The samples were then immediately separated, 
frozen and stored at -80°C until the point of analysis. 
 
 
Canine pro-inflammatory cytokines (IL-2, IL-6, IL-8 and TNF- α) were measured using  Meso 
Scale Discovery (MSD) multi-spot assay system (A division of Meso Scale Diagnostics, LLC. 
9238 Gaither Road, Gaithersburg, MD 20877, USA). This multiplex immunoassay system 
enables the measurement of biomarkers utilising electrochemiluminescent detection. Each 96-
well plate had 4-carbon electrodes in the bottom of each well, each pre-coated with one of the 
anti-cytokine antibodies of interest.  The samples were reconstituted in the assay diluent 
provided. Assay diluent (25 μl) was added to all wells and the plate sealed and incubated for 
30 s at room temperature on an orbital shaker (600 rpm). Samples, standards and controls were 
added at 25 μl per well. The plate was  sealed and incubated for 2 h at room temperature on an 
orbital shaker (600 rpm). At the end  of the incubation the wells were washed three times using 
200 μl PBS+0.05%Tween 20, soaking for 30 s and then discarding. Detection antibody was 
added at 25 μl per well, and the plate sealed and incubated for 1 h at room temperature on an 
orbital shaker (600 rpm). At the end of the incubation the plate was washed three times as 
before. 150 μl of the MSD Read Buffer was added to each well and the MSD plates were 
measured on the MSD Sector Imager 2400 plate reader. The raw data was measured as 
electrochemiluminescence signal (light) detected by photodetectors and analysed using the 
Discovery Workbench 3.0 software  (MSD). A 4-parameter logistic fit curve was generated for 
each analyte using the standards and the concentration of each sample calculated. 
Page | 34  
The plasma concentrations of IL-2, IL-6, IL-8 and TNF- α and ages were compared between 














The cPSS group comprised 36 dogs of 20 different breeds (Table 1). There were 6 neutered 
males, 15 intact males, 13 intact females and 2 neutered females. The median age of the dogs 
in the cPSS group was 12 months (range 3-63 months). Hepatic Encephalopathy was present 
at the time of blood sampling in 29 of the 36 dogs with a cPSS. The healthy control group 
comprised 25 healthy dogs of 17 different breeds (Table 1). There were 5 neutered males, 8 
intact males, 5 intact females and 7 neutered females. The median age of the healthy dogs  was 
15 months (range 3-72 months). There were no significant differences in the median ages of 




There were no significant differences in the plasma concentrations of IL-2, IL-8 and TNF- α 
between the dogs with a cPSS and the healthy dogs (Figure 1, Table 2). There was a significant 
difference (p=0.02) in the median plasma concentration of IL-6 in dogs with a cPSS compared 
to healthy dogs (Figure 1, Table 2). 






















Table 1: Breeds of dogs in cPSS group and healthy group. 
Healthy Control 
Stafordshire Bull Terrier 
Labrador 
Great Dane 
Bearded Collie (2) 
Yorkshire Terrier (2) 

















Jack Russell Terrier (3) 
Dachshund 











Pyrnean Mountain Dog 
Cocker Spaniel 
Shar Pei 










Figure 1: Plasma cytokine concentrations in healthy dogs (control) and dogs with a 







 Healthy cPSS P Value 
IL-2 pg/ml 2.90 4.71 0.12 
IL-6 pg/ml 10.92 21.11 0.02 
IL-8 pg/ml 866.70 589.10 0.79 
TNF-α pg/ml 0.38 0.55 0.38 
 
Table 2 : Median concentrations and p values of plasma IL-2, IL-6, IL-8 and TNF-α in 
healthy dogs and dogs with a congenital portosystemic shunt (cPSS). 
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3.4 Discussion 
 
This study demonstrated that plasma IL-6 concentrations were increased in dogs with cPSS 
compared to healthy dogs whereas other pro-inflammatory cytokines such as TNF-α, IL-2  and 
IL-8 were not significantly different between the two populations of dogs. This finding is 
consistent with a recent study that found that dogs with intra-hepatic diseases had an increase 
in serum IL-6 concentrations[51]. It is also consistent with studies in human patients with 
various liver pathologies. IL-6 concentrations were found to be elevated in patients with acute 
hepatitis and fulminant hepatic failure [52, 53]. Furthermore, IL-6 concentrations were 
increased in patients with chronic liver disease and hepatocellular carcinoma [54, 55]. Hill et 
al. demonstrated that not only were IL-6 concentrations increased in patients with alcoholic 




Increased IL-6 concentrations in dogs with liver diseases may be important in initiating HE, 
which was present in the majority of dogs with a cPSS in this study. Interleukin-6 has been 
shown to be increased in human patients with overt and minimal HE [28, 57]. Additionally, the 
severity of HE positively correlated with serum IL-6 concentrations. Luo et al. demonstrated 
that IL-6 and ammonia were independent predictors of HE and that there was a positive additive 
interaction between IL-6 and ammonia on the presence of HE [28, 57]. Shawcross et al. 
reported that inflammatory mediators, including IL-6 exacerbate neuropsychological 
alterations induced by hyperammonaemia in cirrhotic patients with HE [58]. Together, these 
studies suggest that IL-6 may play an important role in the development of HE. 
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The exact mechanism by which inflammation and hyperammonaemia modulate the 
neuropsychological function remains to be determined. Astrocytes are the main cells in the 
brain that metabolise ammonia. Ammonia is considered to initiate HE through the conversion 
of glutamate and ammonia to glutamine, often resulting in osmotic stress, astrocyte swelling, 




The mechanism by which IL-6 modulates neurological status is unclear although IL-6 can alter 
signal transduction through some neurotransmitter receptors. Chronic exposure to IL-6 alters 
metabotrophic glutamate receptor activated calcium signalling in cerebellar neurons [59]. A 
positive correlation between elevated IL-6 concentrations and increased concentrations of 
neural glutamine was found in patients with acute liver failure. This suggests that IL-6 might 
promote cerebral oedema that is the characteristic of HE [60]. Furthermore, there was a 
negative associated between serum concentrations of IL-6 and memory deficits in patients 
during low dose endotoxemia and IL-6 has been reported to correlate with cognitive decline in 




Interleukin-6 may be involved in the mechanism by which ammonia contributes to the 
pathogenesis of HE. Elevation of serum IL-6 increases fluid phase permeability and ammonia 
diffusion in the central nervous system derived endothelial cells. This leads to increased 
ammonia concentration in the brain and subsequent ammonia toxicity to the central nervous 
system [63]. Experimental models have demonstrated that simultaneous treatment of astrocyte 
cultures with a mixture of IL-6 and ammonia had a marked additive effect on mitochondrial 
permeability transition, leading to astrocyte swelling [64]. 
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Additional studies are required to further examine the role of IL-6 in the development of HE in 
dogs with cPSS. Studies comparing plasma IL-6 concentrations in dogs with a cPSS that have 
HE with IL-6 concentrations in asymptomatic dogs with a cPSS would be informative. In 
addition, the serial measurement of plasma IL-6 concentrations in dogs where their HE grade 
changes or remains static following treatment would also help to clarify the role of IL-6 in 






The study demonstrates that IL-6 concentrations are increased in dogs with a cPSS. Given the 
well-established role of IL-6 in the pathogenesis of hepatic encephalopathy in humans with 
acquired liver disease, it is possible that IL-6 may be important in the development of HE in 
dogs with a cPSS. Additional studies on the role of IL-6 in the pathogenesis of hepatic 
encephalopathy in dogs with both acquired and congenital liver disease are warranted. A better 
understanding of the role of IL-6 and other cytokines in the development of HE may facilitate 
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Hyponatremia is a common clinical pathology abnormality in human patients with advanced 
liver disease, cirrhosis and ascites [47]. Hyponatremia develops due to a disturbance in the 
renal capacity to eradicate solute-free water [47]. This leads to the retention of water that is 
out of proportion to the retention of sodium and consequently a hyponatremia with volume 
excess and increased total body sodium concentrations. This results in a decrease in the 
plasma sodium concentration and hypo-osmolality. The main pathogenic factor in 
hyponatraemia is a non-osmotic hypersecretion of arginine vasopressin from the neurophysis 




One of the most significant complications of hyponatraemia in humans with liver disease is 
the development of hepatic encephalopathy (HE). The mechanism(s) by which hyponatremia 
causes HE in human patients with liver disease is incompletely understood but a shift of 
water into astrocytes which subsequently causes astrocyte swelling is widely regarded to be 
important in the development of HE [47]. In experimental models of acute liver failure, the 
presence of hyponatremia is associated with greater brain swelling compared with normal 
serum sodium concentrations [66]. Furthermore, in patients with acute liver failure and high 
grade HE, the administration of hypertonic saline to increase serum sodium concentration 
reduced the incidence and severity of intracranial hypertension [67]. 
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The hypothesis of this study was that hyponatremia would be a common abnormality in dogs 
with primary hepatitis. The aim of the study was to document serum sodium concentrations 




4.2 Materials and Methods 
 
 
Medical records from dogs that were presented to the University of Edinburgh Small Animal 
Hospital were searched for all cases of primary hepatitis. Cases were only included if the dog 
had histopathological confirmation of parenchymal hepatic disease from samples collected 
either by biopsy or on post-mortem examination. Information on the dog’s signalment and 
previous medical treatment was also extracted. Dogs which had been previously treated with 
diuretics or intravenous fluids were excluded from the study. Disease was classified 
according to WSAVA criteria by a board certified pathologist [2]. The serum sodium 
concentration and the presence or absence of HE was recorded at initial presentation. The 
serum was separated and analysed immediately. The presence of HE was evaluated using 
previously described criteria [43]. The dog was considered to have HE if it had clinical signs 
of lethargy, inappropriate behavior, disorientation, circling, head pressing or seizures. [68]. 





A Mann Whitney U test was used to compare sodium concentrations in dogs with and 
without ascites and in dogs with cirrhosis and non-cirrhotic primary hepatopathies. 
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Fifty three cases of histologically confirmed primary hepatitis were identified. Eleven dogs 
were excluded as they had been treated prior to presentation with diuretics (n= 5) or intra- 
venous fluid therapy (n=4) or insufficient clinical information was present in their medical 
records (n=2). The remaining 42 dogs were comprised of 18 different pure breeds and 3 
cross-breeds. The gender distribution comprised 8 male entire, 12 male neutered, 11 female 
neutered and 11 female entire dogs. The median age was 75 months (range 6 to 180 months). 
The diagnosis of primary hepatitis was confirmed from samples collected at post-mortem 
examination in 9 cases, and from a percutaneous spring-loaded biopsy instrument in 12 cases. 
Twenty-one samples were collected by surgical biopsy techniques. Twenty-four cases were 
diagnosed with chronic hepatitis, 1 case with juvenile hepatic fibrosis, 5 cases with acute 




Thirty nine dogs had sodium concentrations within the reference interval (ref.139-154 
mmol/l). Only 3 of the 42 dogs (7.1%) had serum sodium concentrations out with the normal 
reference interval. Two of these dogs had serum sodium concentrations of less than 139 
mmol/l but more than 130 mmol/l. The first case was a ten year old female neutered 
Labrador. This dog was referred for investigation of acute onset ascites, abdominal pain, 
inappetance, anorexia and lethargy. Serum sodium concentration was 136 mmol/l at the time 
of presentation. Histologic diagnosis was of a severe, subacute hepatopathy with marked, 
multifocal, centrilobular to midzonal and periportal, acute to subacute hepatic necrosis, 
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hepatocyte drop-out, haemorrhage, histiocytic inflammation and bile duct hyperplasia. The 
second case was a five year old female Border collie who was referred for investigation of 
ascites. The dog’s serum sodium concentration was 134 mmol/l at the point of presentation. 
Histological diagnosis was of a chronic active hepatitis. One dog was hypernatremic with a 
sodium value of 160 mmol/l. This case was a six year old male Doberman Pincher referred 
for chronically increased hepatic enzymes, inappetance and weight loss. Histologic diagnosis 
was of chronic hepatitis. Four dogs had clinical signs of HE at the time of measurement of 
sodium concentration. None of the dogs with serum sodium concentrations outside the 




There was no significant difference between sodium concentrations in dogs with and without 
ascites (median with ascites 144.0mmol/l, median without 147.0mmol/l, p=0.06). There was 
no significant difference between sodium concentrations in dogs with cirrhosis compared to 
dogs with non-cirrhotic primary hepatopathies (median cirrhosis 147.5mmol/l, median non- 







The central finding of this study was that abnormal serum sodium concentrations were not 
commonly observed in dogs with primary hepatitis. This observation markedly contrasts with 
the findings from studies of human with liver disease where hyponatremia is frequently 
observed [46, 47, 69]. For example, in a prospective study of 997 patients with cirrhosis the 
prevalence of low serum sodium concentration, as defined by a serum sodium ≤135 mmol/l, 
≤130 mmol/l, ≤125 mmol/l or ≤120 mmol/l, was 49.4%, 21.6%, 5.7%, and 1.2%, respectively 
[65]. Hyponatraemia was present in 29.8% of patients admitted for management of cirrhosis, 
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as defined by a serum sodium concentration of ≤130 mmol/l [70]. Furthermore, the 
prevalence of hyponatremia was 26% in a population of paediatric patients with end stage 
liver disease waiting for liver transplantation (as defined by a serum sodium concentration of 





We recently examined a wide range of clinical and biochemical parameters, including plasma 
sodium concentrations, in dogs with a congenital portosystemic shunt (cPSS) [68]. The 
findings in dogs with a cPSS were very similar to the ones in this study with only one of 120 
dogs with a cPSS having a plasma sodium concentration below 139mmol/l. Taken together, 
this study and our earlier work in dogs with a cPSS, demonstrate that abnormalities in sodium 




Previous work in human patients with liver disease and experimental models of liver failure 
has also linked hyponatremia to the development of HE [46, 47]. In dogs, clinical signs of HE 
can include lethargy, inappropriate behavior, disorientation, circling, head pressing or 
seizures [11]. The pathogenesis of HE in dogs is incompletely understood. Hyperammonemia 
is considered the most important mediator of HE [16] since ammonia has been demonstrated 
to be neurotoxic and plasma ammonia concentrations are frequently increased in dogs with 
liver disease [68]. However, ammonia is unlikely to be the sole mediator of HE in dogs with 
liver disease since it is not absolutely predictive for the presence of neurological disturbances 
[68]. Furthermore, hyperammonemia alone, which can occur in dogs with urea cycle enzyme 
deficiencies, does not typically result in HE [17]. Studies have indicated potential roles for 
hypercortisolism [19], inflammation [22, 68, 72], altered tryptophan metabolism [20] and 
increased plasma concentrations of endogenous benzodiazepines [18] in the development of 
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HE. Dogs with liver disease have also been demonstrated to have an increased whole blood 





Consequently, the incompletely understood pathophysiology of canine HE has stimulated 
research into the role of other factors which could potentially initiate HE in dogs. We have 
previously examined the role of hyponatremia in the development of HE in dogs with a cPSS. 
We performed a, a multivariable analysis of clinical and biochemical parameters in 120 dogs 
with a cPSS found no evidence of an association between sodium concentrations and the 
development of HE in dogs with a cPSS [68]. Although the prevalence of HE in this present 
study was low, we found no evidence which linked abnormalities in sodium homeostasis with 
the development of HE in dogs with primary hepatitis. This study, and our earlier study of 
dogs with a cPSS indicates that hyponatremia is not only rarely observed in dogs with liver 
disease, but is also unlikely to be an important cause of neurological complications in dogs 




It remains unclear why the incidence of hyponatraemia is greater in humans with liver disease 
compared to dogs with liver disease. The difference in the incidence of hyponatremia between 
humans and dogs with liver disease may be due to the different reasons for the development 
of liver disease and the final histopathological findings. Many human patients with liver 
disease have cirrhosis due to alcoholism which may influence the incidence of electrolyte 
disturbances [65]. The reason(s) for the species difference in sodium homeostasis in the 
setting of liver disease is deserving of further study. 





The present study demonstrates that sodium concentrations are rarely outside the reference 
interval in dogs with primary hepatitis. This finding is in contrast with the numerous studies 
of human patients with liver disease. This study, and our earlier work in dogs with a cPSS, 
indicates that hyponatremia is uncommonly observed in dogs with liver disease. In addition, 
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included in this study. 
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CHAPTER 5 
 
Presence of systemic inflammatory response syndrome predicts a poor clinical outcome 
 




Primary hepatopathies are a common cause of morbidity and mortality in dogs with a recent 
study reporting that over 10 per cent of dogs had evidence of chronic hepatitis at post mortem 
examination [1, 9, 74]. Primary hepatitis includes all inflammatory disorders of the hepatic 
parenchyma [2]. In contrast to human medicine, where the type of hepatitis is defined by the 
inciting cause, few causes of chronic hepatitis have been identified in the dog, and the 
majority of cases are idiopathic [2]. Although primary hepatitis can be readily diagnosed in 
dogs through histological examination of a liver biopsy, it remains a challenging and difficult 
disease to treat [1, 8]. Furthermore, it is difficult to offer clients an accurate prognosis at the 




There is a clear need to clarify the relationship between inflammation and outcome in dogs 
with a primary hepatopathy. A more detailed understanding of the relationship between 
inflammation and clinical outcomes may lead to novel therapeutic approaches. The aim of 
this study was to determine the prevalence of systemic inflammation in a cohort of dogs with 
primary hepatopathies, and to then examine the relationship between systemic inflammation 
and patient survival. 
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5.2 Materials and Methods 
 
 
Consecutive cases of dogs diagnosed with primary hepatopathies at the Royal (Dick) School 
of Veterinary Studies or Davies Veterinary Specialists, were considered for inclusion in the 
study. Cases were only included if the dog had histopathological confirmation of primary 
parenchymal hepatic disease. Information on the signalment and previous medical treatment 
was extracted from the clinical records. The histopathological diagnosis was classified 
according to WSAVA (World Small Animal Veterinary Association) criteria by a board 
certified pathologist [2]. All blood samples were taken by a veterinary surgeon as part of 
routine monitoring. The study was approved by The University of Edinburgh Ethics Research 
Committee and the owners of the dogs gave permission for their animals to be used in this 
study. The presence of HE was evaluated using previously described criteria [43]. The dog 
was considered to have HE if it had clinical signs of lethargy, inappropriate behavior, 
disorientation, circling, head pressing or seizures [68]. If the dog displayed none of these 
signs, it was considered not to have HE. The presence of ascites was documented if 
confirmed by ultrasound evaluation. Details of heart rate, respiratory rate, temperature, 
haematology profile and biochemistry profile were recorded. A SIRS score was calculated for 
each dog using methodology previously described [75]. The SIRS score could range from 0-4 
as each dog was given 1 point when they met each of the following criteria: respiratory rate 
greater than 20 min-1; heart rate greater than 120 min-1; total white blood cell (WBC) count 
less than 6 or greater than 16 x10
9 
L-1 and rectal temperature less than 38.1°C or greater than 




Survival of the cohort was initially examined using Kaplan Meier analysis. As some of the 
dogs were alive at the end of follow up, Cox proportional hazard analysis was used to 
Page | 49  
estimate the association between survival and selected co-variates. Initially, a uni-variable 
analysis was performed which explored the relationship between survival and SIRS score. To 
determine if this relationship persisted in the presence of other possible other confounding 
variables, a multivariable cox proportional hazard model was constructed which included 
SIRS score of 0 or 1 (SIRS low) or SIRS score of 2,3 or 4 (SIRS high), sodium, potassium, 
sex, ALT, ALP, bilirubin, red blood cell count, presence of ascites, sex, age and HE score. A 
final model was built based on step wise removal of variables from the initial comprehensive 
model using AIC as a measure of parameter penalised model fit. To confirm the model 
structure, the impact on AIC of both dropping each of the final variables and adding back in 
the dropped variables was investigated. Results are presented as a hazard ratio with 95% CI. 







Eighty cases of histologically confirmed primary hepatopathies were identified. Ten dogs 
were excluded from the study due to incomplete clinical records.  The 70 dogs included in 
this study comprised of 29 different pure breeds and 8 cross-breeds. The sex distribution 
comprised of 12 entire males, 24 neutered males, 24 neutered females and 10 entire female 
dogs. The median age was 75 months (range 6 to 180 months). The diagnosis of a 
hepatopathy was histologically confirmed from samples collected at post-mortem 
examination in 9 cases, and from a percutaneous spring-loaded biopsy instrument in 12 cases. 
Forty nine samples were collected by surgical biopsy techniques. Fifty cases were diagnosed 
with chronic hepatitis (Fig.1), 10 cases with acute hepatitis, 8 cases with cirrhosis (Fig. 2) and 
2 cases with copper associated hepatitis (Fig. 3). Fifty-seven dogs were dead at follow up and 
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13 were alive. Seventeen dogs had a SIRS score of 0, 22 with a score of 1, 25 with a score of 




The median survival time of the 70 dogs was 38.5 days (95% CI 20-215). To explore the 
relationship between a systemic inflammatory response and survival, the median survival of 
dogs with a SIRS score of 0 or 1 (SIRS Low) and dogs with a SIRS score of 2, 3 or 4 (SIRS 
High) was estimated. The median survival of SIRS Low dogs was 231 days (95% CI 78-not 
available/ days) and median survival of SIRS High was 7 days (95% CI 3-25/ days) 
(p<0.001) (Fig. 4). To assess whether this relationship persisted in the presence of other co- 
variates, a Cox proportional hazard model was built. The initial model included SIRS High or 
low, presence of ascites, HE score, sex sodium, potassium, ALT, ALKP, bilirubin, age, sex 
and red blood cell count. The final model after variable selection included SIRS, bilirubin, 
red blood cell concentrations and age (Table 1). The impact of variables dropped from the 
model was confirmed by calculating the impact on model fit (Δ AIC) when they were 
individually added back into the model (Table 2). 
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Fig 1: Liver from a case of chronic hepatitis with islands of hepatocytes separated by bands 
of fibroblasts and collagen, and moderate numbers of macrophages, lymphocytes and plasma 
cells. Haematoxylin and eosin, scale bar = 50 µ m. 




Fig 2: Liver from a case of chronic hepatitis and early cirrhosis showing disruption of the 
lobular architecture and dissecting fibrosis (green). Masson’s trichrome, scale bar = 100 µm. 
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Fig 3: Liver from a case of chronic hepatitis with intracytoplasmic copper accumulation in 
hepatocytes. Rhodanine red, scale bar = 50 µ m. 











Fig. 4: Kaplan-Meier plot of survival time by SIRS High (red solid line) and SIRS Low (blue 
dotted line). Tick marks show censored events. 
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 Hazard Ratio (95 CI) Δ AIC 
SIRS 3.575 (1.857-6.884) 13.3 
Bilirubin 1.003 (1.001-1.005) 5.98 
Red blood cell 0.768 (0.596-0.990) 2.14 




Table 1: Hazard Ratios and 95% confidence interval for terms in final cox proportional 
hazard model. Δ AIC is the increase in AIC if the term is dropped from model. A positive Δ 



















Table 2: Δ AIC for terms not included in final model when added back in final model. A 
positive Δ AIC equates to a poorer model fit. 




In this large two centre study, we have examined, for the first time, the relationship between 
SIRS, a simple marker of inflammation, and clinical outcome in dogs with primary 
hepatopathies. The central finding of this study was that the dogs with a primary hepatopathy 
and a SIRS score of 2, 3 or 4 had a significantly worse clinical outcome than dogs with a 
SIRS score of 0 or 1. This provides evidence that the presence of systemic inflammation is 
associated with a poorer clinical outcome in dogs, which is similar to human patients with 
liver disease. The presence of SIRS was a major predictor of multiple organ failure and 
strongly correlated with short term mortality in patients with alcoholic hepatitis [30]. In 




Inflammation may be associated with a poor outcome in dogs and humans with liver disease 
for several reasons. Intestinal bacterial overgrowth and altered gut permeability in patients 
with liver disease is hypothesised to lead to increased translocation of bacteria and endotoxin 
into the portal circulation [32]. Factors leading to SIRS development in liver disease include 
the impaired phagocytic function of the reticuloendothelial system which allows endotoxin to 
reach the systemic circulation in high concentrations[24]. Lipopolysaccharide (LPS) 
concentrations in the peripheral and portal circulation have been shown to be increased in 
people with liver cirrhosis [68]. Importantly, LPS concentrations have been shown to predict 
mortality in patients with alcoholic hepatitis[30]. Endotoxin will activate monocytes and 
release pro-inflammatory cytokines which have been implicated in the development of 
hepatic complications such as HE, ascites and variceal bleeding [77]. The disturbances in 
systemic and hepatic haemodynamics in alcohol-related (ACLF) have also been associated 
with dysregulated inflammation, multi-organ failure and marked activation of the 
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In our study, the proportion of dogs which had an infection was not accurately defined. In a 
recent study on human patients with alcoholic hepatitis and SIRS, over 60% of patients had 
no evidence of infection on clinical or microbiological criteria [31]. Understanding the 
pathophysiology of sterile inflammation in patients with liver disease with the ambition of 




Predicting the course and prognosis of disease is an important part of veterinary and human 
clinical practice. The development of new prognostic markers with documented significance 
is an important focus of human and veterinary research. Various factors have been 
demonstrated as negative prognostic factors in dogs with primary hepatitis [78]. These 
included jaundice, abdominal fluid wave, microhepatica, ascites, enlarged portal lymph 
nodes, hypoalbuminemia and left shift of neutrophils in the peripheral blood [1]. Consistent 
with our study, total serum bilirubin was also shown as a negative prognostic factor in 
idiopathic canine chronic hepatitis [74]. High bilirubin concentrations has also been 
documented to be associated with a negative outcome in human patients [60, 79]. 
Furthermore, our prognostic association with low red blood cell count is consistent with the 
prediction of poor survival with reduced red blood cell counts after surgery in human patients 




Another finding of this study was that abnormal serum sodium concentrations were not 
commonly observed in dogs with primary hepatitis. This observation contrasts with the 
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findings from studies of human with liver disease where hyponatremia is frequently observed 
[46, 47, 69]. For example, in a prospective study of 997 patients with cirrhosis the prevalence 
of low serum sodium concentration, as defined by a serum sodium ≤135 mmol/l, ≤130 
mmol/l, ≤125 mmol/l or ≤120 mmol/l, was 49.4%, 21.6%, 5.7%, and 1.2%, respectively [65]. 
Borroni et al. reported hyponatraemia in 29.8% of patients admitted for management of 
cirrhosis, as defined by a serum sodium concentration of ≤130 mmol/l [70]. Furthermore, the 
prevalence of hyponatremia was 26% in a population of paediatric patients with end stage 
liver disease waiting for liver transplantation (as defined by a serum sodium concentration of 
≤130 mmol/l) [71]. It remains unclear why humans but not dogs develop hyponatraemia with 
liver disease. We would hypothesise that the differences in the two populations may be due to 




Several studies in human patients with liver disease have examined the role of circulating 
biomarkers as adjunct markers of systemic inflammation such as LPS, procalcitonin and CRP 
[82-84]. Cytokines, including interleukin-6 (IL-6), interleukin-8 (IL-8), tumour necrosis 
factor (TNF) are key mediators of the inflammatory response [34]. Several studies have 
measured circulating cytokine concentrations in patients with liver disease. One marker that 
has been investigated in some detail is IL-6 [54, 61, 72]. Increased serum concentrations of 
IL-6 have been found in people with different inflammatory diseases and has been correlated 
with the severity of the disease, prognosis and outcome [85]. Higher circulation levels of IL-6 
were significantly associated with a higher risk of developing hepatocellular carcinoma [86]. 
IL-6 has also been shown to be a useful prognostic marker for canine critical care patients 
[87]. 
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Our study demonstrates the need to understand more about the development of systemic 
inflammation in dogs with liver disease and to establish whether reducing systemic 






In conclusion, a high SIRS score was found to be associated with a poorer long term survival 
in our study of dogs with primary hepatopathies. Our study demonstrates the need to 
understand more about the cause and consequences of inflammation in dogs with liver 
disorders. Our study demonstrates the need to understand more about the development of 
systemic inflammation in dogs with liver disease and to establish whether reducing systemic 
inflammation improves patient outcomes. The impact of ameliorating inflammation in 
patients with hepatitis is ill defined. Although prednisolone is widely used as first line 
treatment for hepatitis in both dogs and humans, the therapeutic benefits of prednisolone 






We would like to thank the vets, nurses and owners involved in the care of the animals 
included in this study. 
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CHAPTER 6 
 
Thesis Summary and Conclusions 
 
In summary the findings of this thesis provide further information about the pathogenesis of 
canine liver disease. Firstly, whole blood Mn concentrations are increased in dogs with 
primary hepatitis. Taken together with earlier studies, which reported that dogs with cPSS 
had increased Mn concentrations, it is clear that dogs with either primary vascular or primary 
hepatic disease frequently have disturbed Mn homeostasis. The prognostic significance of 
increased Mn concentrations, correlation with severity of histopathological changes or 
acquired shunting fraction and the relationship between Mn and severity of HE in dogs is 




The results of this thesis also highlight that sodium concentrations are rarely outside the 
reference interval in dogs with primary hepatitis. This finding is in contrast with the 
numerous studies of human patients with liver disease. This study, and our earlier work in 
dogs with a cPSS, indicates that hyponatremia is uncommonly observed in dogs with liver 
disease. In addition, we found no evidence which linked alterations in sodium homeostasis to 




The results from chapter two have sought to better understand the role of inflammation in the 
development of HE. IL-6 concentrations are increased in dogs with a cPSS. Given the well- 
established role of IL-6 in the pathogenesis of hepatic encephalopathy in humans with acquired 
liver disease, it is possible that IL-6 may be important in the development of HE in dogs with 
a cPSS. Additional studies on the role of IL-6 in the pathogenesis of hepatic encephalopathy in  
dogs  with  both  acquired and  congenital  liver disease  are warranted.  A 
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better understanding of the role of IL-6 and other cytokines in the development of HE may 




The final important finding from this work is that a high SIRS score was found to be associated 
with a poorer long term survival in our study of dogs with primary hepatopathies. Our study 
demonstrates the need to understand more about the cause and consequences of inflammation 
in dogs with liver disorders. Our study demonstrates the need to understand more about the 
development of systemic inflammation in dogs with liver disease and to establish whether 
reducing systemic inflammation improves patient outcomes. 
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OBJECTIVES: Increased whole blood manganese concentrations have been reported in humans with pri- 
mary liver disease. Due to the neurotoxic effects of manganese, altered manganese homeostasis has 
been linked to the development of hepatic encephalopathy. Whole blood manganese concentrations are 
increased in cases of canine congenital portosystemic shunts, but it remains unclear whether 
         dogs with primary hepatopathies also have altered manganese homeostasis. 
METHODS: Whole blood manganese concentrations were measured by graphite furnace atomic absorp-         
tion spectrometry in 21 dogs with primary hepatitis, 65 dogs with a congenital portosystemic shunt, 
31 dogs with non-hepatic illnesses and 18 healthy dogs. 
RESULTS: The whole blood manganese concentrations were significantly different between dogs with pri- 
mary hepatitis, dogs with non-hepatic illnesses and healthy dogs (P=0·002). Dogs with primary hepa- titis 
had significantly increased whole blood manganese concentrations compared with healthy dogs 
         (P<0·05) and dogs with non-hepatic illnesses (P<0·01). Dogs with primary hepatitis had significantly lower 
whole blood manganese concentration compared with dogs with congenital portosystemic shunts 
(P=0·0005). 
CLINICAL SIGNIFICANCE: Dogs with primary hepatopathies have increased concentrations of whole blood 
manganese although these concentrations are not as high as those in dogs with congenital portosys- 
temic shunts. The role of altered manganese homeostasis in canine hepatic encephalopathy is worthy of 
further study. 
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          INTRODUCTION  
Primary hepatitis includes all inflammatory disorders of the 
hepatic parenchyma (consisting of the functional unit of liver 
lobule, Michalopoulos & DeFrances 1997), apart from those due 
to distant endotoxin release (Rothuizen & van den Ingh 1998, 
Van den Ingh et al. 2006). Primary hepatitis is well recognised 
in dogs, with one study reporting a clinical prevalence of 0·5% 
(Poldervaart et al. 2009). Primary hepatitis may be divided into 
acute and chronic forms, as well as lobular dissecting, granu- 
lomatous and eosinophilic hepatitis as defined by the WSAVA 
according to histological criteria (Van den Ingh et al. 2006). Of 
these, chronic hepatitis appears the most common (Poldervaart 
et al. 2009). The clinical prevalence of chronic hepatitis may 
be an underestimate because post-mortem examination of 200 
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unselected dogs detected the presence of chronic hepatitis in 12% 
of dogs (Watson et al. 2010). In contrast to human medicine, 
where the type of hepatitis is defined by the inciting cause, few 
causes of chronic hepatitis have been identified in the dog, and 
the majority of cases are considered idiopathic (Watson 2004). 
As a result, treatment is symptomatic (Watson 2004) and the 
prognosis for dogs with chronic hepatitis is poor with a reported 
median survival time of 18·3 months (Poldervaart et al. 2009). 
One of the most serious consequences of primary hepatitis is the 
development of hepatic encephalopathy which can cause signifi- 
cant morbidity (Rothuizen 2009). 
The liver has a key role in regulation of many trace elements 
and various trace element abnormalities have been document- 
ed in cases of canine chronic hepatitis (Schultheiss et al. 2002, 
Pressler et al. 2010). Copper metabolism has been investigated 
most extensively and increased hepatic copper concentrations 
have been shown to be both a cause and effect of chronic hepa- 
titis. In Bedlington terriers, a primary genetic defect results in 
copper accumulation within the hepatic parenchyma and subse- 
quent hepatitis due to oxidative damage (Haywood et al. 1996). 
Conversely, chronic hepatitis can result in reduced biliary excre- 
tion of copper and increased hepatic parenchymal concentra- 
tions (Hoffmann et al. 2009). Similarly, increased hepatic iron 
concentrations have also been documented in naturally occur- 
ring and experimental canine chronic hepatitis (Fuentealba et al. 
1997, Schultheiss et al. 2002, Soubasis et al. 2006). Zinc has 
been shown to be an effective treatment for copper-associated 
hepatitis and hepatic and biliary zinc concentrations have been 
investigated in canine chronic hepatitis (Schultheiss et al. 2002, 
Hoffmann et al. 2009, Pressler et al. 2010). 
The impact of primary hepatic disease on the metabolism of 
other trace elements is less well understood in dogs. In particular, 
the liver plays a pivotal role in manganese (Mn) metabolism as 
the majority of gastrointestinally absorbed Mn is removed by the 
liver and excreted into bile such that only approximately 2% of 
absorbed Mn reaches the systemic circulation (Aschner & Asch- 
ner 2005). One experimental study showed that healthy dogs fed 
large quantities of Mn daily for 16 months showed no ill-effects 
and no appreciable increase in blood Mn concentrations. On 
post-mortem examination, liver and bile had the highest con- 
centrations of Mn (Reiman & Minot 1920). Although Mn is an 
essential mineral, Mn toxicity has been reported in humans and 
also in experimental animal models (Keen et al. 2000). Stud- 
ies in humans have shown increased blood Mn concentrations 
and Mn deposition in the central nervous system (CNS) in cases 
of hepatic insufficiency (Versieck et al. 1974, Rose et al. 1999, 
Mizoguchi et al. 2001, Tuschl et al. 2008). The deposition of 
Mn in the CNS is considered to play a role in hepatic encepha- 
lopathy and a direct relationship has been demonstrated between 
blood Mn concentration, magnetic resonance imaging (MRI) 
hyperintensity consistent with Mn deposition and severity of 
encephalopathic score in humans (Layrargues et al. 1995, Spahr 
et al. 1996). In the CNS, Mn is preferentially stored in astrocytes 
such that their Mn concentrations may be up to approximately 
200 times the extracellular concentrations (Tholey et al. 1988). 
Astrocytes are the major cell implicated in the development of 
 
hepatic encephalopathy and dysfunction of the astrocyte by Mn 
is thought to contribute to this (Shawcross & Jalan 2005, Hazell 
et al. 2006). 
There have been only a small number of studies which have 
investigated the role of Mn in canine liver disease. MRI of 13 
dogs and 3 cats with a congenital portosystemic shunt (cPSS) 
detected hyperintense focal areas in the lentiform nuclei which 
were considered to be consistent with Mn deposition, although 
neither blood nor tissue Mn concentrations were assessed (Torisu 
et al. 2005). In support of this hypothesis, a single case has been 
reported of a Yorkshire terrier with a cPSS and a compatible 
hyperintense lentiform nucleus which had an increased concen- 
tration of Mn in this area on post-mortem examination (Torisu 
et al. 2008). A recent study demonstrated that whole blood Mn 
concentrations are increased in cases of canine cPSS (Gow et al. 
2010). However, it remains unclear whether dogs with primary 
hepatitis have altered Mn homeostasis. 
The central hypothesis of this study was that dogs with pri- 
mary hepatitis have altered Mn homeostasis. The aim was to 
compare whole blood Mn concentrations in dogs with primary 
hepatitis with concentrations in healthy dogs and in dogs with 
non-hepatic illness. A second hypothesis was that dogs with pri- 
mary hepatopathies would not have such profound disturbances 
of Mn homeostasis as in dogs with a cPSS. This was investigated 
by comparing whole blood Mn concentrations in dogs with a 
primary hepatopathy and those with a cPSS. 
 
 
 MATERIALS AND METHODS  
 
Study population 
Cases of primary hepatitis, defined as dogs with increased fast- 
ing bile acid concentrations, and histopathological confirmation 
of primary hepatitis from samples collected by either biopsy or 
post-mortem examination were considered eligible for inclusion 
into the study. Disease was classified according to WSAVA crite- 
ria (Van den Ingh et al. 2006). The type of diet during the past 7 
days was noted for each dog. Consecutive cases of dogs with non- 
hepatic illness, defined as dogs with illness warranting diagnostic 
investigations including serum biochemistry which had serum 
concentrations of albumin, alanine aminotransferase (ALT), fast- 
ing bile acid concentrations and bilirubin within their respective 
reference intervals, were enrolled into the study. Dogs with cPSS 
confirmed by ultrasonography and/or portovenography were 
also enrolled. Consecutive cases of healthy dogs, defined as dogs 
which were considered healthy by their owners and had a normal 
physical examination when blood sampled for an unrelated pri- 
mary reason (rabies serology or PCV check before blood dona- 
tion), were also enrolled into the study. 
 
Sampling methods 
Whole blood samples were collected from fasted animals. Surplus 
blood collected via a 21g 5/8˝ hypodermic needle from the jug- 
ular vein for clinical diagnostic purposes was placed into com- 
mercial 1·3 mL Ethylenediaminetetraacetic acid (EDTA) tubes 
and retained for Mn measurement. All EDTA  samples   were 
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frozen within 4 hours of collection and stored at −70°C until 
they were transported on dry ice to the Scottish Trace Element 
and Micronutrient Reference Laboratory. Manganese concentra- 
tions were determined in whole blood by graphite furnace atomic 
absorption spectrometry after dilution with Triton X-100 solu- 
tion. The inter-assay coefficient of variation (CV) was 3·1% and 
the intra-assay CV was 5·4%. 
The study was approved by the University of Edinburgh Eth- 
ics Research Committee and owner consent was obtained. 
 
Statistical analysis 
Manganese concentrations, and differences in age, were com- 
pared between the dogs with primary hepatitis, hospitalised ill 
dogs and healthy dogs by a Kruskal-Wallis test with post-test 
Dunn’s multiple comparison test. Manganese concentrations 
were compared between dogs with primary hepatitis and a cPSS 
by a Mann-Whitney U test. The presence of correlation between 
Mn concentrations and biochemical values and age was evalu- 
ated by Spearman Rank Correlation test. Statistical analysis was 
performed with a commercial software package (GraphPad Prism 
version 5.0 for Windows; GraphPad Software) with P<0·05 con- 
sidered significant. Non-parametric testing was done because of 
the size of the groups under analysis. 
 
 
 RESULTS  
 
The group of dogs with non-hepatic illness comprised 31 dogs 
(19 different breeds, 2 crossbreeds, 4 male entire, 10 male 
neutered, 13 female neutered, 4 female entire, mean age 59·5 
months, range 5 to 132 months). The disease categories were 
nasal disease (n=5), inflammatory disease (n=4), orthopaedic 
abnormalities (n=4), lower urinary tract disorders (n=6), poor 
body condition/exercise intolerance (n=5), chronic renal failure 
(n=2), focal neoplasia (n=2) and one each of ovarian remnant 
syndrome, congenital cardiac disease and rodenticide exposure. 
Blood samples from healthy dogs were obtained from 16 blood 
donors and 2 dogs during rabies serology sampling (10 differ- 
ent breeds, one crossbreed, 4 male entire, 11 male neutered, 3 
female neutered, mean age 57 months, range 24 to 120 months). 
Sixty-five dogs with cPSS (25 breeds, 8 crossbreeds, 21 male 
entire, 10 male neutered, 26 female entire, 8 female neutered, 
mean age 19 months, range 3 to 96 months) were also enrolled. 
Twenty-one dogs diagnosed with primary hepatic disease were 
enrolled (10 different breeds, 6 crossbreeds, 4 male entire, 7 male 
neutered, 10 female neutered, mean age 84 months, range 6 to 
180 months). Eight were confirmed from samples collected dur- 
ing post-mortem examination, and four by using a percutane- 
ous spring-loaded biopsy instrument. Nine were collected by 
surgical biopsy techniques. Eighteen cases were diagnosed with 
chronic hepatitis, two cases with dissecting lobular hepatitis and 
one case with cirrhosis. Only one case was being fed a diet for- 
mulated for liver disease at the time of sampling. The other 20 
dogs were fed a standard proprietary dog food or home cooked 
diet. The dogs with non-hepatic illnesses and healthy dogs were 








FIG 1. Whole blood manganese concentrations (nmol/L) in dogs with 
primary hepatitis (liver), dogs with non-hepatic illness (hospitalised) 




FIG 2. Whole blood manganese concentrations (nmol/L) in dogs with 





significant differences between the age of the dogs in the healthy, 
non-hepatic illness and primary hepatic disease groups (P=0·67). 
There was a significant difference in Mn concentrations 
between dogs with primary hepatic disease, dogs with non- 
hepatic illness and healthy dogs (P<0·002, Fig 1). Post test 
analysis revealed that there was no difference in Mn concentra- 
tions between dogs with non-hepatic illness and healthy dogs 
but a significant difference in Mn concentration between dogs 
with primary hepatic disease and dogs with non-hepatic illness 
(P<0·01) and dogs with primary hepatic disease and healthy dogs 
(P<0·05). In the primary hepatic disease group, there was no cor- 
relation between Mn and fasting bile acid concentrations (r=0·25, 
P=0·28), Mn and albumin concentration (r=−0·19, P=0·41), 
Mn and ALT activity (r=−0·20, P=0·39), Mn and prothrombin 
time (r=0·18, P=0·48), Mn and activated thromboplastin time 
(r=0·35, P=0·16) or Mn and bilirubin concentrations (r=0·07, 
P=0·77). 
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Dogs with primary hepatitis had significantly lower whole 
blood Mn concentration compared to dogs with cPSS (median 
values 1101 and 2026 nmol/L, respectively, P=0·0005; Fig 2). 
There was a significant difference in age between the cPSS (medi- 




 DISCUSSION  
 
The central finding of this study was that whole blood Mn con- 
centrations were significantly higher in dogs with primary hepatic 
disease compared to both healthy dogs and dogs with non-hepatic 
illness. Taken together with an earlier study, which reported that 
dogs with cPSS had increased Mn concentrations, it is clear that 
dogs with either primary vascular or primary hepatic disease fre- 
quently have disturbed Mn homeostasis (Gow et al. 2010). The 
first-pass excretion of gastrointestinally absorbed Mn relies on 
efficient delivery through the portal circulation, and both func- 
tional hepatocytes and a functional biliary system. Dysfunction 
of any one of these three components will potentially increase 
delivery of Mn to the systemic circulation (Krieger et al. 1995, 
Rose et al. 1999). Chronic hepatitis and lobular dissecting hepa- 
titis commonly result in dysfunction of all three components: 
hepatocyte loss by definition in chronic hepatitis, cholestasis 
due to hepatic architecture disruption of the biliary system and, 
because of increased portal pressure, recruitment of portosystemic 
collateral vessels (Rothuizen 2009). Consequently, it is techni- 
cally challenging to establish the relative importance of primary 
parenchymal diseases, cholestasis and portosystemic shunting on 
Mn metabolism. This issue has been partially addressed in exper- 
imental models of liver disease, a study of CNS Mn deposition in 
the rat found that rats with induced portocaval shunts had higher 
concentrations than rats with induced cirrhosis. The shunting 
percentage was 100% for induced shunts, whereas cirrhotic rat 
shunting percentage ranged from 29 to 100% (Rose et al. 1999). 
One clinical study of humans with cirrhosis demonstrated that 
all nine patients with hyperintense lesions on MRI had shunting 
vessels compared to only 2 of 17 patients with no lesions on MRI 
(Inoue et al. 1991). In this study, the finding that whole blood 
Mn concentrations were significantly higher in dogs with cPSS 
compared to dogs with primary hepatopathy would suggest that 
shunting vessels have an important role in the pathogenesis of 
hypermanganesaemia. A further study investigating any correla- 
tion between whole blood Mn concentrations with the percent- 
age shunting in dogs with primary hepatitis would further clarify 
this hypothesis. 
Investigation of whole blood Mn concentrations in cases of 
acute hepatitis may help define the contribution of hepatic dys- 
function per se to increased Mn concentrations. One study of 
acute hepatitis in humans demonstrated increased serum con- 
centrations of Mn in acute hepatitis and found a correlation with 
activity of serum ALT in both acute and chronic hepatitis which 
may suggest that hepatic dysfunction rather than development 
of portosystemic shunting was responsible for the increased sys- 







Determination of systemic whole blood Mn concentrations in 
cases of extra-hepatic cholestasis would also be useful to assess 
the contribution of biliary dysfunction to increased systemic Mn 
concentrations. 
Manganese and iron metabolism are intimately linked. Both 
metals use divalent metal transporter 1 (DMT1) for absorption 
from the gastrointestinal tract and also transport into the CNS 
(Garrick et al. 2003). DMT1 expression in both is regulated by 
iron status via hepcidin (Brasse-Lagnel et al. 2011, Li et al. 2011). 
Deficiency of iron has been shown to increase CNS Mn uptake 
whilst iron overload decreases Mn uptake (Aschner & Aschner 
1990). Hepcidin is mainly produced by hepatocytes and is up- 
regulated in response to inflammation (Park et al. 2001, Nicolas 
et al. 2002). Because chronic hepatitis (by definition) and to a 
lesser extent lobular dissecting hepatitis have an inflammatory 
component, it would be expected that hepcidin may be up-regu- 
lated and this, in turn, would reduce gastrointestinal absorption 
of Mn (Rothuizen 2006). In converse, loss of hepatocytes would 
reduce the liver’s ability to produce hepcidin and thus potentially 
remove negative regulation of DMT1 expression. In support of 
this, serum hepcidin and prohepcidin concentrations have been 
found to be lower in humans with chronic hepatitis C compared 
to healthy controls and correlate with fibrosis (Jaroszewicz et al. 
2008, Tsochatzis et al. 2010). Therefore, it is likely that the 
confounding interplay of inflammation, reduced hepatic func- 
tion, effects of iron status on hepcidin expression and therefore 
gastrointestinal Mn uptake, may all play a role in the variation 
in Mn concentrations found in the primary hepatopathy group. 
In the primary hepatitis group, 5 dogs had whole blood Mn 
concentrations which were markedly elevated whilst the remain- 
ing 16 had similar concentrations to the non-hepatic illness and 
healthy groups. This apparent split may be due to a difference 
in hepatic reserve, or as stated above, due to differing shunt frac- 
tions, and larger studies to assess if histological severity and/or 
shunting fraction correlated with Mn concentrations would be 
informative. 
The main pathological consequence of increased Mn con- 
centrations in hepatic disorders is considered to be neurologi- 
cal dysfunction. The exact mechanism by which Mn causes 
encephalopathy is unclear although there are both in vitro and 
in vivo studies which suggest that many of the effects are cen- 
tred on the astrocyte, a key cell in the development of hepatic 
encephalopathy (Prakash & Mullen 2010). Astrocytes have 
been shown to have a high affinity transport mechanism for 
Mn and cytoplasmic Mn accumulation causes Alzheimer type 
II changes, which are recognized in post-mortem examination 
of human hepatic encephalopathy patients (Hazell et al. 2006, 
Rama Rao et al. 2007). Experimental studies have demonstrated 
a wide variety of potential toxic effects of Mn on the astrocyte, 
including potentiating the effect of ammonia as well as impairing 
their glutamate transport (Jayakumar et al. 2004). Glutamate is 
the main excitatory neurotransmitter in the brain, and astrocyte 
uptake is the main method of removal from the synaptic cleft. 
Glutamate is then converted to glutamine by the astrocyte before 
being recycled back to the neuron. Inhibition of the astrocyte 
glutamate transporter GLT-1 by Mn prevents this  inactivation 
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and recycling, potentially causing increased concentrations of 
the neurotransmitter in the synaptic cleft (Hazell & Butterworth 
1999). Astrocyte mitochondrial dysfunction and induction of 
peripheral-type benzodiazepine receptors (PTBR, now termed 
translocator protein) with increased ligand binding have also 
been reported with increasing concentrations of Mn (Hazell  et 
al. 1999, Yin et al. 2008, Ahboucha 2011). Activation of the 
PTBR causes neurosteroid production, which is also implicated 
in astrocyte dysfunction and hepatic encephalopathy (Hazell & 
Butterworth 1999, Ahboucha 2011). 
The finding that Mn concentrations are increased in some 
dogs with primary hepatopathies may be therapeutically relevant 
since chelation treatment with para-aminobenzoic acid and diso- 
dium edetate has been used successfully in human cases of Mn 
toxicity (Ky et al. 1992, Herrero Hernandez et al. 2006). This 
has led to the suggestion that it may be of use in controlling Mn 
and thus hepatic encephalopathy in humans and dogs (Riordan 
& Williams 1997, Torisu et al. 2008, Tuschl et al. 2008). In sup- 
port of this, Park et al. (2008) used trientine chelation therapy in 
one human case of chronic hepatic disease with acquired porto- 
systemic shunting and hepatic encephalopathy. Following treat- 
ment there was a decrease in whole blood Mn concentrations 
and a reduction in CNS MRI hyperintensity which was thought 
to be consistent with a reduction in CNS Mn deposition. These 




This study demonstrates that whole blood Mn concentrations 
are increased in dogs with primary hepatitis. The prognostic 
significance of increased Mn concentrations, correlation with 
severity of histopathological changes or acquired shunting frac- 
tion and the relationship between Mn and severity of hepatic 
encephalopathy in dogs is deserving of further study. 
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a b s t r a c t   
 
Congenital portosystemic shunts (cPSS) are a well-recognised vascular anomaly in dogs. Recent studies 
have shown an association between inflammation and hepatic encephalopathy (HE), which is a common 
clinical syndrome in dogs with a cPSS. Pro-inflammatory cytokines such as interleukin (IL)-6 and tumour 
necrosis factor (TNF)-a are frequently increased in the plasma of human patients with liver disease and 
have been implicated in the development of HE. 
In the current study, plasma concentrations of IL-2, IL-6, IL-8 and TNF-a were measured using a mul- 
tiplex electrochemiluminescence immunoassay in 36 dogs with a cPSS and compared to 25 healthy dogs. 
There were no significant differences in plasma IL-2, IL-8 and TNF-a concentrations between the two 
groups; however, plasma concentrations of IL-6 were significantly higher in dogs with a cPSS compared 
to healthy dogs (P = 0.02). 
© 2014 Elsevier Ltd. All rights   reserved. 
 
Congenital portosystemic shunts (cPSS) are a well-recognised 
vascular anomaly in dogs. One of the most common clinical signs 
in dogs affected with a cPSS is hepatic encephalopathy (HE). Re- 
cently, we demonstrated the potential role of an inflammatory re- 
sponse, whereby dogs affected with HE, associated with a cPSS, had 
higher serum concentrations of C-reactive protein (CRP), compared 
to healthy dogs or dogs with a cPSS that were asymptomatic (Gow 
et al., 2012). Similar observations have been made in humans af- 
fected with liver disease (Coltart et al., 2013). Several groups of 
researchers have investigated the role of  cytokines, which are 
key mediators of the systemic inflammatory response, in human 
patients with liver disorders, with several of such studies identify- 
ing elevated plasma concentrations of interleukin (IL)-6 and tu- 
mour necrosis factor (TNF)-a (Odeh et al., 2005; Luo et al., 2012a). 
The aim of the current study was to measure IL-2, IL-6, IL-8 and 
TNF-a in the plasma of healthy dogs and in those affected with a 
cPSS. The study was approved by the University of Edinburgh’s 
Veterinary Ethical Review Committee (VERC 110308). Dogs were 
diagnosed with a cPSS if they had compatible clinical signs and 
had an abnormal shunting vessel identified via    ultrasonography, 
 
⇑  Corresponding author at: Royal (Dick) School of Veterinary Studies, Division    of 
computerised tomography, intra-operative portovenography, 
visualised during surgery or by a combination of these methods. 
Healthy dogs, undergoing blood sampling for routine health mon- 
itoring, were included in the study and were defined as those that 
were considered healthy by their owners and who had a normal 
physical examination. Venous blood samples were collected from 
both the cPSS dogs and healthy control animals and immediately 
placed into lithium heparin anticoagulant blood collection tubes. 
Samples were spun then plasma separated, frozen and stored at 
-80 °C until cytokine analysis was performed. 
Canine pro-inflammatory cytokines (IL-2, IL-6, IL-8 and TNF-a) 
were measured using a multiplex electrochemiluminescence 
immunoassay system1 (Meso Scale Discovery; MSD). Assay diluent 
(25 lL) was added to all wells, plates sealed and incubated for      30 
min at room temperature on an orbital shaker (600 rpm). Samples and 
standards, diluted in assay diluent, were added at 25 lL per well. 
Plates were again sealed and incubated for a further 2 h at room 
temperature with shaking. At the end of the incubation period, wells 
were washed three times with 200 lL/well phosphate-buf- fered 
saline (PBS), supplemented with 0.05% Tween 20 (Sigma–Al- drich) 
for  30 s,  then  discarded. Detection antibody  was  added   at 
Veterinary  Clinical  Sciences,  Hospital  for  Small  Animals,  The  University     of    
Edinburgh, Midlothian EH25 9RG, United Kingdom. Tel.: +44 1316 507650. 
E-mail address: Richard.mellanby@ed.ac.uk (R.J. Mellanby). 
1 See: http:// www. mesoscale.com/CatalogSystemWeb/Documents/ 
Canine_ProInflam_Panel_3.pdf. 
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Table 1 
Breeds of dogs in cPSS group and healthy  group. 
 
Healthy control cPSS 
Staffordshire Bull terrier Yorkshire terrier (5) 
Labrador Labrador (4) 
Great Dane Lakeland terrier 
Bearded Collie (2) Irish Wolfhound 
Yorkshire terrier (2) Jack Russell terrier (3) 
Jack Russell terrier (2) Dachshund 
Crossbreed (6) West Highland White terrier (5) 
Weimaraner Pug (4) 
Cocker Spaniel Bichon Frise 
British Bulldog Bassett hound 
Border terrier Crossbreed 
Bull Mastiff Fox terrier 
Border Collie Lhasa Apso 
Lhasa Apso Ibizan hound 
Cavalier King Charles Spaniel Shih Tzu 
Golden Retriever Chihuahua 
Springer Spaniel Border terrier 






25 lL per well, plates sealed and incubated for a further 1 h at room 
temperature with shaking. Plates were washed  three  times  and  150 
lL of MSD Read Buffer added to each well, then electrochemi- 
luminescence measured using the MSD Sector Imager 2400 plate 
reader.  Plasma  cytokine  concentrations  and  ages  were compared 
between the healthy dogs and dogs affected with a cPSS, using the 
Mann Whitney U test with a P-value <0.05 considered to be 
significant. 
The cPSS group consisted of 36 dogs of 20 different breeds (Ta- 
ble 1). There were 15 entire males, six neutered males, 13 entire fe- 
males and two neutered females. The median age of the dogs in the 
cPSS group was 12 months (range 3–63 months). Hepatic enceph- 
alopathy was present at the time of blood sampling in 29/36 dogs with 
a cPSS. The healthy control group comprised 25 healthy dogs of 17 
different breeds (Table 1). There were eight entire males, five 
neutered males, five entire females and seven neutered females.   The 
median age of the healthy dogs was 15 months (range 3–       72 
months). There was no significant difference in the median ages of 
healthy dogs and dogs with a  cPSS. 
There were no significant differences between groups in the 
plasma concentrations of IL-2, IL-8 and TNF-a, but there was a sig- 
nificant difference (P = 0.02) in the plasma IL-6 concentrations 
comparing dogs with a cPSS and healthy dogs (Fig. 1, Table 2). This 
finding is consistent with a recent study that found dogs with in- 
tra-hepatic diseases had increased serum IL-6 concentrations 
(Neumann et al., 2012). It is also consistent with studies in human 
patients with various types of liver pathology (Tilg et al., 1992). 
Increased circulating IL-6 concentrations in dogs with liver 
disease might be an important factor in initiating HE, which was 
present in the majority of dogs with a cPSS in the present study. 
IL-6 has been shown to be increased in human patients with overt 























Fig. 1. Plasma IL-2, IL-6, IL-8 and TNF-a concentrations in healthy dogs and dogs with a congenital portosystemic shunt (cPSS), measured by electrochemiluminescence 
immunoassay. The median cytokine concentration is shown as a horizontal line for each group.  
 
Table 2 
Median concentrations and P-values of plasma IL-2, IL-6, IL-8 and TNF-a in healthy dogs and dogs with a congenital portosystemic shunt (cPSS). 
 
Cytokine Healthy (pg/mL) cPSS (pg/mL) P-value Lower limit of detection (pg/mL) Upper limit of detection (pg/mL) 
IL-2 2.90 4.71 0.12 1.38 20,000 
IL-6 10.92 21.11 0.02 3.01 10,000 
IL-8 866.70 589.10 0.79 0.31 10,000 
TNF-a 0.38 0.55 0.38 0.20 5000 
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(Luo et al., 2012a,b). The mechanism by which IL-6 could poten- 
tially modulate neurological status is unclear, although chronic 
exposure to IL-6 alters metabotrophic glutamate receptor-acti- 
vated calcium signalling in cerebellar neurons, which could pro- 
mote cerebral oedema (Nelson et al., 2004). Furthermore, 
elevated IL-6 concentrations have been reported to correlate with 
cognitive decline in humans (Weaver et al., 2002). 
IL-6 might be involved in the mechanism by which ammonia 
contributes to the pathogenesis of HE. Experimental models have 
demonstrated that simultaneous treatment of astrocyte cultures 
with a mixture of IL-6 and ammonia had a marked additive effect 
on mitochondrial permeability transition, leading to astrocyte 
swelling (Alvarez et al., 2011). Future studies examining the cause 
of the increased plasma IL-6 concentration and longitudinally, 
monitoring IL-6 concentrations following treatment in a large co- 
hort of dogs would be informative. 
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Primary hepatopathies are a common cause of morbidity and mortality in dogs. The underly- 
ing aetiology of most cases of canine hepatitis is unknown. Consequently, treatments are 
typically palliative and it is difficult to provide accurate prognostic information to owners. In 
human hepatology there is accumulating data which indicates that the presence of systemic 
inflammatory response syndrome (SIRS) is a common and debilitating event in patients 
with liver diseases. For example, the presence of SIRS has been linked to the development 
of complications such as hepatic encephalopathy (HE) and is associated with a poor clinical 
outcome in humans with liver diseases. In contrast, the relationship between SIRS and clini- 
cal outcome in dogs with a primary hepatitis is unknown. Seventy dogs with histologically 
confirmed primary hepatitis were enrolled into the study. Additional clinical and clinicopatho- 
logical information including respiratory rate, heart rate, temperature, white blood cell count, 
sodium, potassium, sex, presence of ascites, HE score, alanine aminotransferase (ALT), 
alkaline phosphatase (ALP), bilirubin and red blood cell concentration were available in all 
cases. The median survival of dogs with a SIRS score of 0 or 1 (SIRS low) was 231 days 
compared to a median survival of 7 days for dogs with a SIRS score of 2, 3 or 4 (SIRS high) 
(p<0.001). A Cox proportional hazard model, which included all other co-variables, revealed 
that a SIRS high score was an independent predictor of a poor clinical outcome. The effect 
of modulating inflammation on treatment outcomes in dogs with a primary hepatitis is 







Primary hepatopathies are a common cause of morbidity and mortality in dogs, with a recent 
study reporting that over 10 per cent of dogs had evidence of chronic hepatitis at post mortem 
examination [1–3 ]. Primary hepatitis includes all inflammatory disorders of the hepatic 
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parenchyma [ 4]. In contrast to human medicine, where the type of hepatitis is defined by the 
inciting cause, few causes of chronic hepatitis have been identified in the dog, and the majority 
of cases are idiopathic [ 4]. Although primary hepatitis can be readily diagnosed in dogs 
through histological examination of a liver biopsy, it remains a challenging and difficult disease 
to treat [ 1, 5 ]. Furthermore, it is difficult to offer clients an accurate prognosis at the time of 
diagnosis [2 ]. 
There is growing evidence that systemic inflammatory response syndrome (SIRS) is a com- 
mon and serious disorder among human patients with liver diseases [ 6–8 ]. It has been sug- 
gested that the presence of SIRS can lead to a further deterioration in liver function resulting in 
significant morbidity and mortality [9, 10]. The presence of SIRS can compromise the function 
of various organ systems resulting in Multiple Organ Dysfunction Syndrome (MODS) [11]. 
Hospitalised human patients with cirrhosis and SIRS have more severe hepatic encephalopathy 
(HE), are more likely to develop hepatorenal syndrome and have non-reversible renal dysfunc- 
tion [1 2]. In acute liver failure, the presence of SIRS, whether or not precipitated by infection, 
has been implicated in the progression of HE, reducing the chances of transplantation and con- 
ferring a poorer prognosis [13]. Furthermore, higher SIRS scores are related to the develop- 
ment of acute liver failure in patients with pre-existing hepatitis [1 4]. 
There is a clear need to clarify the relationship between inflammation and outcome in dogs 
with a primary hepatitis. A more detailed understanding of the relationship between inflamma- 
tion and clinical outcomes may lead to novel therapeutic approaches. The aim of this study was 
to determine the prevalence of systemic inflammation in a cohort of dogs with primary hepati- 
tis, and to then examine the relationship between systemic inflammation and patient survival. 
 
 
Materials and Methods 
Consecutive cases of dogs diagnosed with primary hepatopathies at the Royal (Dick) School of 
Veterinary Studies or Davies Veterinary Specialists, were considered for inclusion in the study. 
Cases were only included if the dog had histopathological confirmation of primary parenchy- 
mal hepatic disease. Information on the signalment and previous medical treatment was 
extracted from the clinical records. The histopathological diagnosis was classified according to 
WSAVA (World Small Animal Veterinary Association) criteria by a board certified pathologist 
[4]. All blood samples were taken by a veterinary surgeon as part of routine clinical manage- 
ment of each patient. The study was approved by The University of Edinburgh Ethics Research 
Committee and the owners of the dogs gave permission for their animals’ data to be used in 
this study. 
The presence of HE was evaluated using previously described criteria [15]. The dog was 
considered to have HE if it had clinical signs of lethargy, inappropriate behavior, disorienta- 
tion, circling, head pressing or seizures [ 16]. If the dog displayed none of these signs, it was 
considered not to have HE. The presence of ascites was documented if confirmed by ultra- 
sound evaluation. Details of heart rate, respiratory rate, temperature, haematology profile and 
biochemistry profile were recorded. A SIRS score was calculated for each dog using methodol- 
ogy previously described [17]. The SIRS score could range from 0–4 as each dog was given 1 
point when they met each of the following criteria: respiratory rate greater than 20 min heart 
rate greater than 120 min; total white blood cell (WBC) count less than 6 or greater than 16 
x109 L and rectal temperature less than 38.1°C or greater than 39.2°C Therefore, a SIRS score 
could range from 0 to 4. 
Survival of the cohort was initially examined using Kaplan Meier analysis. As some of the 
dogs were alive at the end of follow up, Cox proportional hazard analysis was used to estimate 
the association between survival and selected co-variates. Initially, a uni-variable analysis was 
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performed which explored the relationship between survival and SIRS score. To determine if 
this relationship persisted in the presence of other possible other confounding variables, a mul- 
tivariable Cox proportional hazard model was constructed which included SIRS score of 0 or 1 
(SIRS low) or SIRS score of 2, 3 or 4 (SIRS high), sodium, potassium, sex, ALT, ALP, bilirubin, 
red blood cell count, presence of ascites, age and HE score. A final model was built based on 
step wise removal of variables from the initial comprehensive model using AIC as a measure of 
parameter penalised model fit. To confirm the model structure, the impact on AIC of both 
dropping each of the final variables and adding back in the dropped variables was investigated. 
Results are presented as a hazard ratio with 95% CI. Statistical analysis was performed in R sta- 
tistical software package (R Development Core Team (2012)). 
 
Results 
Eighty cases of histologically confirmed primary hepatopathies were identified. Ten dogs were 
excluded from the study due to incomplete clinical records. The 70 dogs included in this study 
comprised of 29 different pure breeds and eight cross-breeds. The sex distribution comprised 
of 12 entire males, 24 neutered males, 24 neutered females and 10 entire female dogs. The 
median age was 75 months (range 6 to 180 months). The diagnosis of hepatitis was histologi- 
cally confirmed from samples collected at post-mortem examination in 9 cases, and from a per- 
cutaneous spring-loaded biopsy instrument in 12 cases. Forty nine samples were collected by 
surgical biopsy techniques. Fifty cases were diagnosed with chronic hepatitis (Fig 1), 10 cases 
with acute hepatitis, eight cases with cirrhosis (Fig 2) and two cases with copper associated hep- 
atitis (Fig 3). Fifty-seven dogs were dead at follow up and 13 were alive. Seventeen dogs had a 
SIRS score of 0, 22 had a score of 1, 25 had a score of 2, five had a score of 3 and one dog had a 
score of 4. 
 
Fig 1. Liver from a case of chronic hepatitis with islands of hepatocytes separated by bands of 
fibroblasts and collagen, and moderate numbers of macrophages, lymphocytes and plasma cells. 
Haematoxylin and eosin, scale bar = 50 μm. 
 
doi:10.1371/journal.pone.0146560.g001 
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Fig 2. Liver from a case of chronic hepatitis and early cirrhosis showing disruption of the lobular 




The median survival time of the 70 dogs was 38.5 days (95% CI 20–215). To explore the 
relationship between a systemic inflammatory response and survival, the median survival of 
dogs with a SIRS low and dogs with a SIRS high was estimated. The median survival of SIRS 
low dogs was 231 days (95% CI 78-not available/ days) and median survival of SIRS high was 7 
 
Fig 3. Liver from a case of chronic hepatitis with intracytoplasmic copper accumulation in hepatocytes. 
Rhodanine red, scale bar = 50 μm. 
doi:10.1371/journal.pone.0146560.g003 
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Fig 4. Kaplan-Meier plot of survival time in days by SIRS high (red solid line) and SIRS low (blue 




days (95% CI 3-25/ days) (p<0.001) (F ig 4). To assess whether this relationship persisted in the 
presence of other co-variates, a Cox proportional hazard model was built. The initial model 
included SIRS high or low, presence of ascites, HE score, sex, sodium, potassium, ALT, ALP, 
bilirubin, age, sex and red blood cell count ( S1 File). The final model after variable selection 
included SIRS, bilirubin, red blood cell concentrations and age ( Table 1). The impact of vari- 
ables dropped from the model was confirmed by calculating the impact on model fit (Δ AIC) 




In this large two centre study, we have examined for the first time, the relationship between 
SIRS, a simple marker of inflammation, and clinical outcome in dogs with primary hepatitis 
The central finding of this study was that the dogs with a primary hepatitis and a SIRS score of 
2, 3 or 4 had a significantly worse clinical outcome than dogs with a SIRS score of 0 or 1. This 
provides evidence that the presence of systemic inflammation is associated with a poorer clini- 
cal outcome in dogs, which is similar to human patients with liver disease. The presence of 
SIRS was a major predictor of multiple organ failure and strongly correlated with short term 
mortality in patients with alcoholic hepatitis [7]. In addition, SIRS has recently been associated 
with acute on chronic liver failure (ACLF) [18]. 
 
Table 1.   Hazard Ratios and 95% confidence interval for terms in final Cox proportional hazard model.    Δ 
AIC is the increase in AIC if the term is dropped from the model. A positive Δ AIC equates to a poorer model fit. 
Hazard Ratio (95% CI) Δ AIC 
SIRS 3.575 (1.857–6.884) 13.3 
Bilirubin 1.003 (1.001–1.005) 5.98 
Red blood cell 0.768 (0.596–0.990) 2.14 
Age 0.909 (0.827–1.000) 1.94 
doi:10.1371/journal.pone.0146560.t001 
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Table 2. Δ AIC for terms not included in final model when added back in final model. A positive Δ AIC 











Inflammation may be associated with a poor outcome in dogs and humans with liver disease 
for several reasons. Intestinal bacterial overgrowth and altered gut permeability in patients 
with liver disease is hypothesised to lead to increased translocation of bacteria and endotoxin 
into the portal circulation [9]. Factors leading to SIRS development in liver disease include the 
impaired phagocytic function of the reticuloendothelial system which allows endotoxin to 
reach the systemic circulation in high concentrations [ 13]. Lipopolysaccharide (LPS) concen- 
trations in the peripheral and portal circulation have been shown to be increased in people 
with liver cirrhosis. Importantly, LPS concentrations have been shown to predict mortality in 
patients with alcoholic hepatitis[7]. Endotoxin can activate monocytes and release pro-inflam- 
matory cytokines which have been implicated in the development of hepatic complications 
such as HE, ascites and variceal bleeding [ 19]. The disturbances in systemic and hepatic hae- 
modynamics in alcohol-related liver failure (ACLF) have also been associated with dysregu- 
lated inflammation, multi-organ failure and marked activation of the sympathetic nervous 
system [7]. These abnormalities predict high mortality rates in these patients [8]. 
  
In our study, the proportion of dogs which had an infection was not accurately defined. In a 
recent study of human patients with alcoholic hepatitis and SIRS, over 60% of patients had no 
evidence of infection, based on clinical or microbiological criteria [8]. Understanding the 
pathophysiology of sterile inflammation in patients with liver disease, with the ambition of 
developing targeted therapies, is one of the major challenges in contemporary hepatology. 
Predicting the course and prognosis of disease is an important part of veterinary and 
human clinical practice and the development of new prognostic markers with documented sig- 
nificance is an important focus of human and veterinary research. Various factors have been 
demonstrated as negative prognostic indictors in dogs with primary hepatitis [ 20]. These 
include jaundice, abdominal fluid wave, microhepatica, ascites, enlarged portal lymph nodes, 
hypoalbuminemia and left shift of neutrophils in the peripheral blood [1]. Consistent with our 
study, total serum bilirubin was a negative prognostic indicator in idiopathic canine chronic 
hepatitis [2]. High bilirubin concentrations have also been documented to be associated with a 
negative outcome in human patients [21, 22]. Furthermore, our prognostic link with low red 
blood cell count is consistent with the prediction of poor post-surgical survival associated with 
reduced red blood cell counts in human patients with primary liver cancer [23] and end stage 
liver disease [24]. 
Another finding of this study was that abnormal serum sodium concentrations were not 
commonly observed in dogs with primary hepatitis. This observation contrasts with the find- 
ings from studies of humans with liver disease where hyponatremia is frequently observed [25– 
 27]. For example, in a prospective study of 997 patients with cirrhosis the prevalence of low 
serum sodium concentration, defined as a serum sodium ::;135 mmol/l, ::;130 mmol/l, ::;125 
mmol/l or ::;120 mmol/l, was 49.4%, 21.6%, 5.7%, and 1.2%, respectively [28]. Borroni et al. 
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reported hyponatraemia in 29.8% of patients admitted for management of cirrhosis, as defined 
by a serum sodium concentration of ::;130 mmol/l [29]. Furthermore, the prevalence of hypo- 
natremia was 26% in a population of paediatric patients with end stage liver disease awaiting 
liver transplantation (as defined by a serum sodium concentration of ::;130 mmol/l) [ 30]. It 
remains unclear why humans frequently develop hyponatraemia with liver disease while dogs 
do not. We hypothesise that the differences may reflect the different causes of liver disease in 
dogs compared to humans. 
Several studies in human patients with liver disease have examined the role of circulating 
biomarkers as adjunctive markers of systemic inflammation, such as LPS, procalcitonin and C 
reactive protein [ 31– 33]. Cytokines, including interleukin-6 (IL-6), interleukin-8 (IL-8) and 
tumour necrosis factor (TNF), are key mediators of the inflammatory response [1 1]. Several 
studies have measured circulating cytokine concentrations in patients with liver disease. One 
marker that has been investigated in some detail is IL-6 [34–36]. Increased serum concentra- 
tions of IL-6 have been found in people with different inflammatory diseases and has been cor- 
related with the severity of disease, prognosis and outcome [37]. Higher circulation levels of 
IL-6 were significantly associated with a higher risk of developing hepatocellular carcinoma 
[38]. IL-6 has also been shown to be a useful prognostic marker for canine critical care patients 
[39]. 
Our study demonstrates the need to understand more about the development of systemic 
inflammation in dogs with liver disease and to establish whether reducing systemic inflamma- 
tion improves outcomes. 
 
Conclusion 
In conclusion, a high SIRS score was associated with poorer long term survival in our study of 
dogs with primary hepatitis Our study demonstrates the need to understand more about the 
causes and consequences of inflammation in dogs with liver disorders. Our study demonstrates 
the need to understand more about the development of systemic inflammation in dogs with 
liver disease and to establish whether reducing systemic inflammation improves patient out- 
comes. The impact of ameliorating inflammation in patients with hepatitis is ill defined. 
Although prednisolone is widely used as a first line treatment for hepatitis in both dogs and 
humans, its therapeutic benefits remain ill-defined in both species [40–43]. 
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